<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:yt="http://gdata.youtube.com/schemas/2007" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
   <channel>
      <title>SDBN Blogs News Jobs</title>
      <description>Pipes Output</description>
      <link>http://pipes.yahoo.com/pipes/pipe.info?_id=84139d6373fab4295ad87c78c91a817f</link>
      <atom:link rel="next" href="http://pipes.yahoo.com/pipes/pipe.run?_id=84139d6373fab4295ad87c78c91a817f&amp;_render=rss&amp;page=2" />
      <pubDate>Thu, 31 May 2012 10:48:05 +0000</pubDate>
      <generator>http://pipes.yahoo.com/pipes/</generator>
      <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/sdbn" /><feedburner:info xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" uri="sdbn" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><feedburner:emailServiceId xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0">sdbn</feedburner:emailServiceId><feedburner:feedburnerHostname xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0">http://feedburner.google.com</feedburner:feedburnerHostname><item>
         <title>Lab Assistant - BioPhase Solutions -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Lab-Assistant-at-BioPhase-Solutions-in-San-Diego,-CA-a7dcfc995213083e</link>
         <description>are currently looking for a Lab Assistant to work for a leading San Diego biotechnology company.   Lab Assistant The Laboratory Assistant is expected to have... &lt;br/&gt;
            From BioPhase Solutions - 31 May 2012 08:05:50 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">90dd1a5d094544b611fbdf172f4dbbf7</guid>
         <pubDate>Thu, 31 May 2012 08:05:50 +0000</pubDate>
      </item>
      <item>
         <title>Process Development Engineer - BP International Ltd -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Process-Development-Engineer-at-BP-International-in-San-Diego,-CA-99eef50d5251a5e9</link>
         <description>required; graduate degree preferred.  • 7-10+ years’ experience in biotechnology, bioprocessing, chemicals, or petrochemicals R&amp;amp;D; process design; or process... &lt;br/&gt;
            From Energyjobs.com - 30 May 2012 23:50:35 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">47d8b15603b4fdc25ceaf6a0339703c1</guid>
         <pubDate>Wed, 30 May 2012 23:50:35 +0000</pubDate>
      </item>
      <item>
         <title>NuVasive to Participate in Investor Events in June 2012</title>
         <link>http://www.marketwire.com/mw/release.do?id=1663404&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will participate in seve...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 20:30:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  NuVasive, Inc. ( NASDAQ : NUVA ), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will participate in several investor events in June 2012. </p>
        <p>Michael J. Lambert, Executive Vice President and Chief Financial Officer, is scheduled to present at the Goldman Sachs Global Healthcare Conference at the Terranea Resort Hotel in Rancho Palos Verdes, CA, on Tuesday, June 5, 2012, at 10:40 a.m. PDT.</p>
        <p>Alex Lukianov, Chairman of the Board and Chief Executive Officer, is scheduled to present at the William Blair Growth Stock Conference at the Four Seasons Hotel in Chicago, IL, on Tuesday, June 12, 2012 at 10:10 a.m. CDT.</p>
        <p>A live webcast of each event will be available online from the investor relations page of the Company's corporate website at <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=893257&id=1661179&type=1&url=http://www.nuvasive.com/">www.nuvasive.com</a>. After the live webcast, a replay will remain available on the website for 30 days.</p>
        <p><span style="text-decoration:underline;">About NuVasive<br />
        </span>NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 5<sup>th</sup> largest player in the $7.6 billion global spine market.</p>
        <p>NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS<sup>®</sup> platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess<sup>®</sup>, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF<sup>®</sup>, NuVasive has built an entire spine franchise. With over 70 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness<sup>®</sup>. </p>
        <p><em>NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=893257&id=1661182&type=1&url=http://www.sec.gov/">www.sec.gov</a>. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.</em></p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Sr. Director of Compliance - BioPhase Solutions Inc -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Senior-Director-Compliance-at-BioPhase-Solutions-in-San-Diego,-CA-d3e79bf777b007fe</link>
         <description>looking for a Sr. Director of Compliance to work for a leading San Diego biotechnology company. Sr. Director of Compliance  The purpose of this position is to... &lt;br/&gt;
            From Monster - 30 May 2012 18:06:13 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">eb3c261df3caeda273907fe116a5adcf</guid>
         <pubDate>Wed, 30 May 2012 18:06:13 +0000</pubDate>
      </item>
      <item>
         <title>Regional Clinical Research Associate (CRA)* - ICON -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Regional-Clinical-Research-Associate-at-ICON-in-San-Diego,-CA-d1ac52926386fc61</link>
         <description>provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in a highly fragmented industry... &lt;br/&gt;
            From Icon - 30 May 2012 17:54:51 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">d196e4e56799def94af4404d08547c47</guid>
         <pubDate>Wed, 30 May 2012 17:54:51 +0000</pubDate>
      </item>
      <item>
         <title>Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate</title>
         <link>http://www.marketwire.com/mw/release.do?id=1663303&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion ...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 17:17:51 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today announced that data related to the company's oncolytic viral therapy, GL-ONC1, will be presented in a poster session at the 2012 American Society of Clinical Oncology (ASCO) annual meeting from June 1<sup>st</sup> to June 5<sup>th</sup> in Chicago, IL. The data relate to the completed Phase 1 clinical trial of GL-ONC1 administered to patients with advanced solid tumors and show preliminary evidence of anti-tumor activity with Stable Disease observed in 33% of patients (9 of 27) across a range of cancers.</p>
        <p>"GL-ONC1, our leading product candidate, has been well-tolerated and shown encouraging results in early human trials against a number of solid tumor cancers. It is based on a novel product platform that delivers therapeutic and diagnostic constructs in the same potential therapy directly to tumors without harming healthy tissues or cells," said Dr. Aladar A. Szalay, founder and CEO of Genelux Corporation. </p>
        <p>Details of the poster session follow:</p>
        <p>Abstract No. 2530: Phase I Clinical Trial of a Genetically Modified and Oncolytic Vaccinia Virus GL-ONC1 with Green Fluorescent Protein Imaging. Poster to be presented in S406 on June 2<sup>nd</sup>, 2012 from 8:00 a.m. to 12:00 p.m. and discussed in the Developmental Therapeutics - Clinical Pharmacology and Immunotherapy session immediately following from 12:00 pm to 1:00 pm in S406. </p>
        <p><strong>About Genelux Corporation</strong></p>
        <p>Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic virus-based technology platform featuring a companion optical imaging [luminescent/fluorescent] diagnostic capability on a therapeutic, replication-competent Lister strain vaccinia virus backbone. It is designed to selectively find and kill cancer cells without harming healthy tissues or cells. The platform can also be "customized" by inserting desired genes to effectively treat a variety of cancers and cancer-related conditions. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company's lead oncology product candidate, is an attenuated (Lister strain) vaccinia virus currently under evaluation in human clinical trials in Europe and sponsored by Genelux GmbH, a wholly owned subsidiary of Genelux Corporation. Additional US- and European-based trials are set to begin imminently. For more information, please visit <a rel="nofollow" target="_blank" href="http://www.genelux.com/">www.genelux.com</a>.</p>
        <p><strong>Genelux Forward Looking Statement</strong></p>
        <p>Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.  </p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Senior Recruiter - Etech Hi Inc. -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Senior-Recruiter-at-Etech-Hi-in-San-Diego,-CA-00c0d3e56ecad9ba</link>
         <description>and have experience in industries such as: Construction, Engineering, Biotechnology, Medical, Nursing, Insurance, Legal, Pharmaceutical, Environmental, Finance...  $150,000 a year&lt;br/&gt;
            From Etech Hi Inc. - 30 May 2012 13:29:57 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">8b896557e9c02c244811afbf92824312</guid>
         <pubDate>Wed, 30 May 2012 13:29:57 +0000</pubDate>
      </item>
      <item>
         <title>Ardea Biosciences Earns Milestone From Bayer HealthCare</title>
         <link>http://www.marketwire.com/mw/release.do?id=1663032&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:30:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Ardea Biosciences, Inc. ( NASDAQ : RDEA ) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications. The milestone was triggered by the initiation of the Phase 2 part of a previously reported Phase 1/2 clinical study evaluating the investigational agent BAY 86-9766 in combination with gemcitabine for the treatment of advanced pancreatic cancer. </p>
        <p><strong>About BAY 86-9766<br />
        </strong>BAY 86-9766 (RDEA119) is an investigational agent that is not approved by FDA, EMA, or other health authority and is being developed under a global license agreement with Bayer. BAY 86-9766 is currently in Phase 2 clinical development in patients with hepatocellular carcinoma in combination with sorafenib and in patients with advanced pancreatic cancer in combination with gemcitabine.</p>
        <p><strong>About Ardea<br />
        </strong>Ardea is a biotechnology company based in San Diego, California, focused on the development of small-molecule therapeutics for the treatment of serious diseases. Ardea's most advanced clinical-stage product candidates include lesinurad, formerly known as RDEA594, and BAY 86-9766, formerly known as RDEA119. Lesinurad is a selective, oral URAT1 transporter inhibitor for the chronic management of hyperuricemia in patients with gout, and BAY 86-9766 is a specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer which is being developed under a global license agreement with Bayer HealthCare. On April 21, 2012, Ardea entered into an agreement and plan of merger pursuant to which AstraZeneca PLC will acquire Ardea for $32.00 per share in cash, through a reverse merger of a subsidiary of AstraZeneca with and into Ardea. Upon completion of the merger, Ardea will be a subsidiary of AstraZeneca. The total transaction value is approximately $1.26 billion. Ardea expects the completion of the merger, which is subject to various customary conditions, including approval by Ardea's stock holders, in the second or third quarter of 2012. For more information please visit: <a rel="nofollow" target="_blank" href="http://www.ardeabio.com/">www.ardeabio.com</a></p>
        <p><strong>Forward-Looking Statements<br />
        </strong>Statements contained in this communication regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the timing and anticipated completion of the proposed merger, the benefits and synergies expected to result from the proposed merger, the anticipated customer base for Ardea following the completion of the proposed merger, Ardea's plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119), RDEA3170 and Ardea's other compounds and the timing and results of Ardea's preclinical, clinical and other studies, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Ardea and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include any difficulties associated with integrating Ardea's drug development programs into AstraZeneca's operations, potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger, unexpected costs, charges or expenses resulting from the proposed merger, litigation or adverse judgments relating to the proposed merger, risks relating to the consummation of the contemplated merger, including the risk that the required stockholder approval might not be obtained in a timely manner or at all or that other closing conditions will not be satisfied, any difficulties associated with requests or directions from governmental authorities resulting from their reviews of the transaction, and any changes in general economic and/or industry-specific conditions, risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with Ardea's drug discovery and development programs, and risks related to the outcome of Ardea's business development activities, including collaboration or license agreements. Certain of these and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including Ardea's Annual Report on Form 10-K and Ardea's Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this communication speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</p>
        <p><strong>Additional Information and Where to Find It<br />
        </strong>In connection with the proposed merger described in this communication (the "Merger"), a proxy statement of Ardea and other materials will be filed with the SEC. COMPANY INVESTORS ARE URGED TO READ THE PROXY STATEMENT AND OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARDEA AND THE PROPOSED MERGER. Investors will be able to obtain copies of the proxy statement (when available) and other relevant documents filed with the SEC for free from the SEC's website at <a rel="nofollow" target="_blank" href="http://www.sec.gov/">http://www.sec.gov</a> or from Ardea's website at <a rel="nofollow" target="_blank" href="http://www.ardeabio.com/">http://www.ardeabio.com</a>. Stockholders will also be able to obtain copies of the proxy statement and other documents related to the Merger (when available) for free by written request to Ardea Biosciences, Inc., c/o Corporate Secretary, 4939 Directors Place, San Diego, California 92121.</p>
        <p><strong>Participants in Solicitation<br />
        </strong>Ardea and its directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed Merger. Information about the executive officers and directors of Ardea and their ownership of Ardea's common stock is set forth in the proxy statement for Ardea's 2012 Annual Meeting of Stockholders filed with the SEC on April 10, 2012. Certain directors and executive officers of Ardea may have direct or indirect interests in the Merger due to securities holdings, pre-existing or future indemnification arrangements, vesting of options or other securities or rights to severance payments if their employment is terminated following the Merger. Additional information regarding Ardea and the interests of its executive officers and directors in the Merger will be contained in the proxy statement regarding the Merger that will be filed by Ardea with the SEC. </p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Ardea Biosciences, Inc. Earns $7.5 Million Milestone From Bayer HealthCare</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=261986&amp;full=1</link>
         <description>&lt;div&gt;&lt;p&gt;SAN DIEGO, CA--(Marketwire - May       30, 2012) -    Ardea Biosciences, Inc. (NASDAQ: &lt;a rel="nofollow"&gt;RDEA&lt;/a&gt;) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase ...&lt;/div&gt;</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Cytori Therapeutics, Inc. Obtains Celution(R) Approval in Russia; to Launch Product Line for Plastic Surgery and Select Soft Tissue Therapies</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=261984&amp;full=1</link>
         <description>&lt;div&gt;&lt;p&gt;SAN DIEGO, CA--(Marketwire - May       30, 2012) -    Cytori Therapeutics (NASDAQ: &lt;a rel="nofollow"&gt;CYTX&lt;/a&gt;) has obtained approval to sell the Celution&amp;#174; 800 System in Russia for various medical uses. These clinical uses are based on those in the current European CE Mark, and include the use of the Celution&amp;#174; system and its...&lt;/div&gt;</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Ligand Pharmaceuticals Inc. Partner GlaxoSmithKline Submits US and European Regulatory Applications for use of PROMACTA/REVOLADE to Increase Platelet Counts in Patients with Hepatitis C</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=262036&amp;full=1</link>
         <description>SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc announced today that it has submitted regulatory applications in the United States and European Union related to eltrombopag (Promacta/Revolade) and its use to increase platelet counts in patients with chronic hepatitis C virus infection and low platelets (thrombocytopenia), specifically:</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Zogenix, Inc. Submits IND for Second DosePro(R) Candidate Relday(TM)</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=261996&amp;full=1</link>
         <description>SAN DIEGO, May 30, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food &amp; Drug Administration (FDA) for Relday, which is a combination of Zogenix's DosePro needle-free...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>TrovaGene, Inc. Announces Pricing of Public Offering of 1,150,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=262088&amp;full=1</link>
         <description>&lt;div&gt;&lt;p&gt;&lt;span&gt;SAN DIEGO&lt;/span&gt;, &lt;span&gt;May 29, 2012&lt;/span&gt; /PRNewswire/ -- &lt;b&gt;Trovagene, Inc. &lt;/b&gt;(Nasdaq: TROVD),&lt;b&gt;&lt;/b&gt;a developer of trans-renal molecular diagnostics, announced the pricing of an underwritten public offering of 1,150,000 units at an offering price of &lt;span&gt;$8.00&lt;/span&gt; per unit, with each unit consisting of...&lt;/div&gt;</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Amylin Pharmaceuticals, Inc. to Present at Jefferies and Co. 2012 Global Healthcare Conference and Goldman, Sachs &amp; Co. 33rd Annual Global Healthcare Conference</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=262061&amp;full=1</link>
         <description>SAN DIEGO--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) will be presenting at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5 at 1:30 p.m. ET/10:30 a.m. PT in New York and at the Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6 at 2:20 p.m. ET/11:20 a.m. PT in Rancho Palos Verdes, California. Mark G. Foletta, senior vice president, finance...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Illumina, Inc. to Webcast Live Presentations at Upcoming Investment Conferences in June</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=262077&amp;full=1</link>
         <description>SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the company's presentations at two upcoming investment conferences. Illumina will webcast its presentation at the Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California, on June 6, 2012. The live webcast is scheduled to begin at 12:20 p.m. ET and will feature an overview of the company...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Isis Pharmaceuticals, Inc. to Present at the Goldman, Sachs &amp; Co. 33rd Annual Global Healthcare Conference</title>
         <link>http://www.biospace.com/news_story.aspx?StoryID=262072&amp;full=1</link>
         <description>&lt;div&gt;&lt;p&gt;&lt;span&gt;CARLSBAD, Calif.&lt;/span&gt;, &lt;span&gt;May 30, 2012&lt;/span&gt; /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 33rd Annual Global Healthcare Conference on &lt;span&gt;Tuesday, June 5, 2012&lt;/span&gt; at...&lt;/div&gt;</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
      </item>
      <item>
         <title>Cytori Obtains Celution(R) Approval in Russia; To Launch Product Line for Plastic Surgery and Select Soft Tissue Therapies</title>
         <link>http://www.marketwire.com/mw/release.do?id=1662987&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical uses. These clinical uses are based on those in the current European CE Mark, and i...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 30 May 2012 12:00:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Cytori Therapeutics ( NASDAQ : CYTX ) has obtained approval to sell the Celution<sup>®</sup> 800 System in Russia for various medical uses. These clinical uses are based on those in the current European CE Mark, and include the use of the Celution<sup>®</sup> system and its output of adipose-derived stem and regenerative cells (ADRCs) for plastic surgery and select soft tissue therapies.</p>
        <p>The Celution<sup>®</sup> system and related products will be sold into Russia for these indications exclusively through Cytori's distribution partner Human Stem Cells Institute of Moscow (HSCI). HSCI develops and commercializes a diverse portfolio of cell and gene-based treatments. With Cytori, they intend to initially target physicians and clinics seeking to perform a full range of soft tissue procedures such as injections, autologous fat grafting and tissue repair procedures. </p>
        <p>"This regulatory achievement and the distribution partnership with HSCI gives us immediate access to the Russian market through an established and scientifically driven organization with a sales and marketing team already trained and knowledgeable in cell therapy," said Clyde W. Shores, Executive Vice-President of Marketing & Sales. "We anticipate beginning to see the incremental impact from Russian sales starting in the second half of 2012. This approval is an important achievement and helps fulfill our stated 2012 goal to obtain additional market approvals for our technology."</p>
        <p>Russia is now the 11<sup>th</sup> largest medical market in the world and is experiencing double digit growth. The plastic and reconstructive surgery market, which is predominately private pay, represents a part of this growth. Specifically, more than 25,000 anatomical soft tissue augmentations and an additional estimated 12,000 fat grafting procedures are performed each year in Russia. </p>
        <p><strong>About Human Stem Cells Institute</strong></p>
        <p>Human Stem Cells Institute (<a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=892871&id=1657261&type=1&url=http://eng.hsci.ru/">eng.hsci.ru</a>) is Russia's first public biotech company and was founded in 2003. The main focus of HSCI is research and development as well as commercialization and marketing of innovative proprietary products and services in the areas of cell-based and gene and post-genomic technologies. Additionally, HSCI owns the largest family cord blood stem cells bank in Russia -- <em>Gemabank</em><sup>®</sup>.</p>
        <p><strong>About Cytori</strong></p>
        <p>Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution<sup>®</sup> system product family. <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=892871&id=1657264&type=1&url=http://www.cytori.com/">www.cytori.com</a></p>
        <p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
        <p>This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our ability to successfully develop the market for Celution<sup>®</sup> in Russia, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include the challenges inherent in convincing physicians and patients to adopt the new technology, creating and implementing a successful marketing and sales strategy, as well as our history of operating losses, regulatory uncertainties, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2011. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.</p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Basic Biology: The Complex Core of Drug Discovery</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/-tptCw4Tp3M/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191654</guid>
         <pubDate>Wed, 30 May 2012 07:05:27 +0000</pubDate>
         <content:encoded><![CDATA[The hardest task in major league sports is hitting a baseball. Those who can successfully do this even three out of every ten times over the course of a career are likely to find themselves enshrined...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/-tptCw4Tp3M" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Scientific Software Engineer / Architect, Methods Development - Dart NeuroScience LLC -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Scientific-Software-Engineer-at-Dart-NeuroScience-in-San-Diego,-CA-1207ed85260b2aaa</link>
         <description>a related scientific field (Ph.D. a plus), with 5+ years experience in biotechnology/pharmaceutical industry.   Hands-on experience in the software engineering... &lt;br/&gt;
            From Dart NeuroScience LLC - 30 May 2012 04:11:16 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">c5b06776f00a824af58a0f0bed5f553d</guid>
         <pubDate>Wed, 30 May 2012 04:11:16 +0000</pubDate>
      </item>
      <item>
         <title>Business Data Analyst, Service Innovation and Support - TalentBurst, Inc. -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Business-Data-Analyst-at-TalentBurst-in-San-Diego,-CA-6b2bc4e9d96d7ee5</link>
         <description>finance or related background Prior experience in the Life Science or Biotechnology industry preferred Able to manage and prioritize multiple ongoing tasks... &lt;br/&gt;
            From TalentBurst, Inc. - 30 May 2012 03:14:23 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">298c1291dc970a3bdac4454eed1850e5</guid>
         <pubDate>Wed, 30 May 2012 03:14:23 +0000</pubDate>
      </item>
      <item>
         <title>US Compensation &amp; Global Programs Lead (Senior Manager level) - Illumina, Inc. -  San Diego, CA</title>
         <link>http://www.indeed.com/job/US-Compensation-Global-Program-Lead-at-Illumina-in-San-Diego,-CA-d378b9d32a8b8e2b</link>
         <description>experience working in cross-functional teams. • Experience in life sciences, biotechnology, technology or related industry preferred. • Must be hands on and... &lt;br/&gt;
            From WorldatWork - 29 May 2012 23:04:35 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">8a842cf3e50aaddc57cabe9654677e75</guid>
         <pubDate>Tue, 29 May 2012 23:04:35 +0000</pubDate>
      </item>
      <item>
         <title>Business Data Analyst Job - Yoh -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Business-Data-Analyst-at-Yoh-in-San-Diego,-CA-c738efb9adc38388</link>
         <description>finance or related background.  - Prior experience in the Life Science or Biotechnology industry preferred.  - Able to manage and prioritize multiple ongoing... &lt;br/&gt;
            From Yoh Services, LLC - 29 May 2012 20:42:06 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">8a89afac5c2697d6b7a4e5329c848ca5</guid>
         <pubDate>Tue, 29 May 2012 20:42:06 +0000</pubDate>
      </item>
      <item>
         <title>Customer Service Specialist Job - Yoh -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Customer-Service-Specialist-at-Yoh-in-San-Diego,-CA-c789ab02ad7db40e</link>
         <description>or business required.  - At least two years of industrial experience with a biotechnology company required, preferably in the fields of custom oligonucleotide... &lt;br/&gt;
            From Yoh Services, LLC - 29 May 2012 20:42:06 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">70989311bf4629671c9b8ce29e3f25d9</guid>
         <pubDate>Tue, 29 May 2012 20:42:06 +0000</pubDate>
      </item>
      <item>
         <title>Vertex Shares Drop on Mistake in Cystic Fibrosis Drug Data</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/eNjVzIJ5p1Q/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191574</guid>
         <pubDate>Tue, 29 May 2012 14:22:37 +0000</pubDate>
         <content:encoded><![CDATA[Vertex Pharmaceuticals saw its stock rocket on news earlier this month that its two-drug combo treatment for cystic fibrosis showed a strong benefit in a clinical trial, but the stock is coming back...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/eNjVzIJ5p1Q" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Safety Analyses Lead Sangart to Move Ahead with ‘Oxygen Therapeutic’</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/YkpHpwlKTeg/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191506</guid>
         <pubDate>Tue, 29 May 2012 05:41:40 +0000</pubDate>
         <content:encoded><![CDATA[Encouraging results in a second mid-stage trial of an oxygen-carrying compound has prompted San Diego’s Sangart to draw on an additional $50 million from Leucadia National (NYSE: LUK), a diversified...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/YkpHpwlKTeg" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Scientist, Neurogenetics - Dart NeuroScience LLC -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Scientist-at-Dart-NeuroScience-in-San-Diego,-CA-50c39449f048a158</link>
         <description>significant opportunity to develop scientific and managerial skills in a biotechnology environment. The selected candidate will work in a creative, fast-paced... &lt;br/&gt;
            From Dart NeuroScience LLC - 29 May 2012 04:08:43 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">14ada9a14a41b2cc92072a357eebce88</guid>
         <pubDate>Tue, 29 May 2012 04:08:43 +0000</pubDate>
      </item>
      <item>
         <title>Contracts Administrator - LegalStaff -  San Diego, CA</title>
         <link>http://www.indeed.com/job/Contract-Administrator-at-LegalStaff-in-San-Diego,-CA-73e189e267973745</link>
         <description>An International Biotechnology company is seeking a Contracts Administrator. This position will: Be responsible for contracts drafting, evaluation, negotiation... &lt;br/&gt;
            From CareerBuilder - 26 May 2012 10:59:13 GMT
            -  View all &lt;a rel="nofollow" target="_blank" href="http://www.indeed.com/l-San-Diego,-CA-jobs.html"&gt;San Diego jobs&lt;/a&gt;</description>
         <guid isPermaLink="false">7420387f92b01b889a9097b7a126b979</guid>
         <pubDate>Sat, 26 May 2012 10:59:13 +0000</pubDate>
      </item>
      <item>
         <title>Xconomist of the Week: Evan Snyder—Stem Cell Reality Check</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/duxBzG6IV2k/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191373</guid>
         <pubDate>Fri, 25 May 2012 14:13:02 +0000</pubDate>
         <content:encoded><![CDATA[San Diego Xconomist Evan Snyder has been called a “stem cell revolutionary” and is regarded as a father in the field of stem cell research. When we talked in his office at San Diego’s Sanford-Burnham...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/duxBzG6IV2k" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>La Jolla Pharmaceutical Announces Results of Annual Stockholders Meeting</title>
         <link>http://www.marketwire.com/mw/release.do?id=1661693&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 25, 2012) -  La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) (the "Company" and "La Jolla") held its 2012 Annual Meeting of Stockholders on May 22. All matters submitted to a vote of the stockholders ...</description>
         <guid isPermaLink="false" />
         <pubDate>Fri, 25 May 2012 12:30:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 25, 2012) -  La Jolla Pharmaceutical Company ( OTCQB : LJPC ) ( PINKSHEETS : LJPC ) (the "Company" and "La Jolla") held its 2012 Annual Meeting of Stockholders on May 22. All matters submitted to a vote of the stockholders at the Annual Meeting were approved and all director nominees were elected. </p>
        <p>The stockholders approved the following proposals 1) election of George Tidmarsh, M.D., Ph.D. to serve as a director until the 2014 Annual Meeting, 2) election of Saiid Zarrabian to serve as a director until the 2015 Annual Meeting, 3) ratification of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012; 4) amendment of the Company's 2010 Equity Incentive Plan to increase the number of shares that are available for issuance, and 5) approval of the change in the Company's corporate domicile from Delaware to California. </p>
        <p>A high percentage of shares (90.3%) were voted. A total of 10,732,261 shares of common stock were present or represented by valid proxy at the Annual Meeting. The number of shares of common stock entitled to vote was 11,884,137. </p>
        <p>The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below: </p>
        <p><strong>(i) (A) Election of one Class I Director </strong></p>
        <p>Director Nominee <br />
        Saiid Zarrabian<br />
        8,161,125 Votes For, 8,547 Votes Withheld. </p>
        <p><strong>(i) (B) Election of one Class III Director </strong></p>
        <p>Director Nominee <br />
        George Tidmarsh, M.D., Ph.D.<br />
        8,161,055 Votes For, 8,617 Votes Withheld.<br />
        There were 2,562,589 broker non-votes regarding the election of directors. </p>
        <p><strong>(ii) Ratification of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012</strong></p>
        <p>10,570,326 votes for, 161,677 votes against, and 258 votes abstained. <br />
        There were no broker non-votes regarding this proposal. </p>
        <p><strong>(iii) Approval of an amendment to the La Jolla Pharmaceutical Company 2010 Equity Incentive Plan to increase the number of shares that are available for issuance </strong></p>
        <p>8,147,206 votes for, 12,091 votes against, and 10,375 votes abstained. <br />
        There were 2,562,589 broker non-votes regarding this proposal.</p>
        <p><strong>(iv) Approval of the change in the Company's corporate domicile from Delaware to California </strong></p>
        <p>8,157,020 votes for, 11,399 votes against, and 1,253 votes abstained. <br />
        There were 2,562,589 broker non-votes regarding this proposal.</p>
        <p><strong>About La Jolla Pharmaceutical Company<br />
        </strong>La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure.</p>
        <p><strong>Forward Looking Statement Safe Harbor<br />
        </strong>This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site at <a rel="nofollow" target="_blank" href="http://www.sec.gov/">http://www.sec.gov</a>. These risks include, but are not limited to, risks relating to the development of GCS-100, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.</p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>La Jolla Pharmaceutical Announces Results of Annual Stockholders Meeting</title>
         <link>http://www.marketwire.com/mw/release.do?id=1661693&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 25, 2012) -  La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) (the "Company" and "La Jolla") held its 2012 Annual Meeting of Stockholders on May 22. All matters submitted to a vote of the stockholders ...</description>
         <guid isPermaLink="false" />
         <pubDate>Fri, 25 May 2012 12:30:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 25, 2012) -  La Jolla Pharmaceutical Company ( OTCQB : LJPC ) ( PINKSHEETS : LJPC ) (the "Company" and "La Jolla") held its 2012 Annual Meeting of Stockholders on May 22. All matters submitted to a vote of the stockholders at the Annual Meeting were approved and all director nominees were elected. </p>
        <p>The stockholders approved the following proposals 1) election of George Tidmarsh, M.D., Ph.D. to serve as a director until the 2014 Annual Meeting, 2) election of Saiid Zarrabian to serve as a director until the 2015 Annual Meeting, 3) ratification of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012; 4) amendment of the Company's 2010 Equity Incentive Plan to increase the number of shares that are available for issuance, and 5) approval of the change in the Company's corporate domicile from Delaware to California. </p>
        <p>A high percentage of shares (90.3%) were voted. A total of 10,732,261 shares of common stock were present or represented by valid proxy at the Annual Meeting. The number of shares of common stock entitled to vote was 11,884,137. </p>
        <p>The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below: </p>
        <p><strong>(i) (A) Election of one Class I Director </strong></p>
        <p>Director Nominee <br />
        Saiid Zarrabian<br />
        8,161,125 Votes For, 8,547 Votes Withheld. </p>
        <p><strong>(i) (B) Election of one Class III Director </strong></p>
        <p>Director Nominee <br />
        George Tidmarsh, M.D., Ph.D.<br />
        8,161,055 Votes For, 8,617 Votes Withheld.<br />
        There were 2,562,589 broker non-votes regarding the election of directors. </p>
        <p><strong>(ii) Ratification of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012</strong></p>
        <p>10,570,326 votes for, 161,677 votes against, and 258 votes abstained. <br />
        There were no broker non-votes regarding this proposal. </p>
        <p><strong>(iii) Approval of an amendment to the La Jolla Pharmaceutical Company 2010 Equity Incentive Plan to increase the number of shares that are available for issuance </strong></p>
        <p>8,147,206 votes for, 12,091 votes against, and 10,375 votes abstained. <br />
        There were 2,562,589 broker non-votes regarding this proposal.</p>
        <p><strong>(iv) Approval of the change in the Company's corporate domicile from Delaware to California </strong></p>
        <p>8,157,020 votes for, 11,399 votes against, and 1,253 votes abstained. <br />
        There were 2,562,589 broker non-votes regarding this proposal.</p>
        <p><strong>About La Jolla Pharmaceutical Company<br />
        </strong>La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure.</p>
        <p><strong>Forward Looking Statement Safe Harbor<br />
        </strong>This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC's web site at <a rel="nofollow" target="_blank" href="http://www.sec.gov/">http://www.sec.gov</a>. These risks include, but are not limited to, risks relating to the development of GCS-100, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.</p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Nokia Joins X Prize in $2.25M Wireless Health “Sensing Challenge”</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/TJG7a6MQJDA/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191313</guid>
         <pubDate>Thu, 24 May 2012 20:16:45 +0000</pubDate>
         <content:encoded><![CDATA[When the X Prize Foundation’s Peter Diamandis took the stage in San Diego this morning at the Wireless-Life Sciences Alliance (WLSA) annual convergence summit, he said it was the perfect audience for...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/TJG7a6MQJDA" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Nokia Sensing X CHALLENGE — Searching the World for the Most Powerful Digital Health Sensors to Transform the Healthcare Industry</title>
         <link>http://www.marketwire.com/mw/release.do?id=1661425&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 24, 2012) -  The X PRIZE Foundation and Nokia today announced the launch of the Nokia Sensing X CHALLENGE, a $2.25 million global competition to stimulate the development of a new generation of health sensors and sens...</description>
         <guid isPermaLink="false" />
         <pubDate>Thu, 24 May 2012 17:11:43 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 24, 2012) -  The <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647883&type=1&url=http://www.xprize.org/">X PRIZE Foundation</a> and Nokia today announced the launch of the <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647886&type=1&url=http://www.nokiasensingxchallenge.org/">Nokia Sensing X CHALLENGE,</a> a $2.25 million global competition to stimulate the development of a new generation of health sensors and sensing technologies that can drastically improve the quality, accuracy and ease of monitoring a person's health. Improvements in these technologies will empower individuals to effortlessly monitor and collect their own real-time health data, providing both consumers and healthcare providers convenient access to critical information whenever and wherever they need it.</p>
        <p>The announcement was made by X PRIZE Foundation Chairman and CEO Dr. Peter H. Diamandis and Nokia Executive Vice President and Chief Technology Officer Dr. Henry Tirri during their keynote address at the Wireless Health Convergence Summit in San Diego, Calif.</p>
        <p>"Partnering with Nokia is a natural fit for this competition. Health sensing technologies enabled by artificial intelligence, lab-on-a-chip, and digital imaging are advancing exponentially and will ultimately integrate with your phone. We need to expand sensor and sensing technology beyond disease management to areas such as public health and fitness," said <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647889&type=1&url=http://www.linkedin.com/pub/peter-diamandis/0/3bb/539">Dr. Diamandis</a>. "The Nokia Sensing X CHALLENGE will bring about radical innovation in health sensors and sensing technologies, which paves the way for better choices in when, where, and how individuals receive care. Ultimately, healthcare will be more convenient, affordable, and accessible to consumers worldwide through these integrated digital health solutions."</p>
        <p>The inefficiencies and total cost of the U.S. healthcare system (and healthcare systems around the globe) has been a pressing social and political issue for many years. In the U.S., the total spent annually on the healthcare system is more than $2 trillion<sup>1</sup>, which accounts for more than 15 percent of the nation's gross domestic product. Health sensors have the capacity to stem this trend. Consumer use of sensors and sensing solutions has the potential to improve, extend and ease delivery of healthcare services, as well as reduce costs to the benefit of health providers and patients.</p>
        <p>"Nokia engages in Open Innovation on many different levels; this type of 'grand challenge' is not only a unique method of driving significant progress in a short space of time, but one which can also help to create an entire ecosystem," said <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647892&type=1&url=http://research.nokia.com/people/henry_tirri">Dr. Tirri</a>. "This competition will enable us to realize the full potential of mobile sensing devices, leading to advances in sensing technology, which can play a major role in transforming the lives of billions of people around the world."</p>
        <p>The Nokia Sensing X CHALLENGE will be a series of three competition events, held over the next three years. Each event will be comprised of three phases: Registration, Preliminary Judging and Final Phase Judging. The winners of each competition will be the teams that submit best in class technology as determined by a non-partisan judging panel of cross-functional industry experts.</p>
        <p>It is anticipated that the solutions developed as part of the Nokia Sensing X CHALLENGE may also be utilized as part of a team's effort to win the $10 million <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647895&type=1&url=http://www.qualcommtricorderxprize.org/">Qualcomm Tricorder X PRIZE</a>, which was announced at the 2012 Consumer Electronics Show (CES) during Qualcomm Incorporated Chairman and CEO and Qualcomm Foundation Chair Dr. Paul Jacobs' keynote address. The Qualcomm Tricorder X PRIZE is a global competition aiming to drive development of devices that allow consumers access to healthcare in the palm of their hands. The Nokia Sensing X CHALLENGE and Qualcomm Tricorder X PRIZE will help create an ecosystem of innovators and innovative technology that will help reinvent the healthcare industry and radically reduce the cost to consumers.</p>
        <p>For more information about the Nokia Sensing X CHALLENGE, visit: <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647898&type=1&url=http://nokiasensingxchallenge.org/">nokiasensingxchallenge.org</a>. </p>
        <p><strong>About X PRIZE Foundation<br />
        </strong>Founded in 1995, the X PRIZE Foundation, a 501(c)(3) nonprofit, is the leading organization solving the world's Grand Challenges by creating and managing large-scale, high-profile, incentivized prize competitions that stimulate investment in research and development worth far more than the prize itself. The organization motivates and inspires brilliant innovators from all disciplines to leverage their intellectual and financial capital for the benefit of humanity. The X PRIZE Foundation conducts competitions in five Prize Groups: Education; Exploration; Energy & Environment; Global Development; and Life Sciences. Active prizes include the $30 million Google Lunar X PRIZE, the $10 million Archon Genomics X PRIZE presented by Express Scripts, the $10 million Qualcomm Tricorder X PRIZE, and the $2.25 million Nokia Sensing X CHALLENGE. For more information, go to <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647901&type=1&url=http://www.xprize.org/">www.xprize.org</a>. </p>
        <p><strong>About Nokia <br />
        </strong>Nokia is a global leader in mobile communications whose products have become an integral part of the lives of people around the world. Every day, more than 1.3 billion people use their Nokia to capture and share experiences, access information, find their way or simply to speak to one another. Nokia's technological and design innovations have made its brand one of the most recognized in the world. For more information, visit <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647904&type=1&url=http://www.nokia.com/about-nokia">http://www.nokia.com/about-nokia</a>. </p>
        <p>Social Tags:</p>
        
        <ul style="list-style-type:disc;">
            <li>Facebook: <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647907&type=1&url=https://www.facebook.com/xprize">Nokia Sensing X CHALLENGE</a>
            </li>
<li>Twitter: <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647910&type=1&url=https://twitter.com/nokiaxchallenge">@NokiaXCHALLENGE</a>, hashtag: #sensing</li>
        </ul>
        
        <p>TRICORDER is a trademark of CBS Studios, Inc. used under license. Qualcomm is a registered trademark of Qualcomm Incorporated. All other trademarks are the property of their respective owners.</p>
        <p><sup>1</sup>Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group; U.S. Department of Commerce, Bureau of Economic Analysis; and U.S. Bureau of the Census. Retrieved from <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891483&id=1647913&type=1&url=https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/tables.pdf">https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads//tables.pdf</a> </p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>True Diagnostics Receives CE Mark for TrueDX(TM) Platform &amp; TSH Test</title>
         <link>http://www.marketwire.com/mw/release.do?id=1661410&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 24, 2012) -  True Diagnostics, Inc.T (www.TrueDiagnostics.com) has announced it has received a CE Mark to allow it to distribute its TrueDX Platform and quantitative TSH (Thyroid Stimulating Hormone) test in Europe. W...</description>
         <guid isPermaLink="false" />
         <pubDate>Thu, 24 May 2012 16:52:19 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 24, 2012) -  True Diagnostics, Inc.T (<a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891482&id=1647718&type=1&url=http://www.truediagnostics.com/">www.TrueDiagnostics.com</a>) has announced it has received a CE Mark to allow it to distribute its TrueDX Platform and quantitative TSH (Thyroid Stimulating Hormone) test in Europe. With the TrueDX Platform, doctors can immediately determine if a patient suffers from a hypoactive thyroid by using only a finger prick of blood. This unique test enables doctors and patients to gain access to diagnosis in minutes, create an effective treatment plan, while saving physicians' time and patients cost and anxiety. True Diagnostics is actively engaging distribution partners throughout all EU markets, with initial focus in Germany, UK, France, Italy and Spain. </p>
        <p>This is the second regulatory clearance for the TrueDX Platform with TSH test, having received sFDA approval for China in September 2011. True Diagnostics expects to run short clinical studies in the U.S. this summer and further submit for CLIA-waive and 510k FDA clearance to market the TrueDX Platform with quantitative TrueDX-TSHT Tests throughout the U.S.</p>
        <p><strong>What will the TrueDX Platform mean for doctors and patients seeking to more easily identify Hypoactive Thyroid?</strong> Hypothyroidism affects over 200 million people globally, more than people with diabetes. TSH is the fourth most requested blood test in America. Hypothyroidism is commonly undiagnosed and misdiagnosed with symptoms ranging from weight gain to depression, forgetfulness, hair loss, thinning and drying of skin, fatigue, loss of libido, feeling cold, constipation, and a pronounced goiter. </p>
        <p>Jerry Lee, President/CEO of True Diagnostics, notes, "With this latest regulatory clearance, the Company has laid the foundation to begin standardizing a full range of diagnostic and monitoring tests that will provide instant results to doctors and patients and demand little training. With distribution partners already lined up and more coming soon, we expect initial shipments to Europe to begin within 60 days."</p>
        <p>The strength of the TrueDX Platform lies in its simplicity. Tests have a 24-month shelf life. They do not need to be refrigerated. Laboratory quality results from small samples can now be available to doctors to review in minutes. The TrueDX Platform's simplicity, portability, and affordability allow it to be easily adopted into emerging markets. The platform's flexible design also permits it to stay ahead of potential competitors and quickly commercialize a myriad of new biomarkers discoveries for cancer, autism, alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections, and more. In essence, any biomarker discovery utilizing traditional lab methods, such as an ELISA process, can now be developed into a simple, fast, and portable assay which can offer quick diagnosis and treatment right in the physician's office.</p>
        <p><strong>About the Company<br />
        </strong>True Diagnostics, Inc. creates simple diagnostic solutions for the $46 billion medical point-of-care, sterility assurance, animal health, and food processing markets. After 30 years in the global medical diagnostic field, the inventor of the home pregnancy test created the TrueDX Platform which can measure the severity of any medical condition (using only a finger prick of blood, small urine or saliva sample, toxins, surface bacteria, and more), provide results in minutes (not days), and is completely portable. The TrueDX Platform takes point-of-care, point-of-incidence, and remote-of-care applications out of the lab to provide more flexible treatment that can begin immediately. The TrueDX Platform creates unique and powerful opportunities for new diagnostic solutions through its ability to: 1) quickly bring new diagnostic tests to market; and, 2) open new geographic and application opportunities.</p>
        <p>For more information, call <strong><span style="white-space:nowrap;" class="baec5a81-e4d6-4674-97f3-e9220f0136c1">760-683-9158</span> </strong>or go to <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=891482&id=1647721&type=1&url=http://www.truediagnostics.com/">www.TrueDiagnostics.com</a> </p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>SD Life Sciences Roundup: Takeda Consolidates, Startups Raise Cash</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/Xm7Yw-o_G50/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191232</guid>
         <pubDate>Thu, 24 May 2012 14:38:04 +0000</pubDate>
         <content:encoded><![CDATA[It’s been a busy week for startup funding, with Obalon Therapeutics, Aperio Technologies, Topera, and Ivera Medical closing on financing deals. We’ve also got drug development news from Ocera...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/Xm7Yw-o_G50" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>MediciNova Misses Primary Goal in Mid-Stage Trial of IV Asthma Drug</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/lHdRFKmWmgo/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=191194</guid>
         <pubDate>Wed, 23 May 2012 23:58:24 +0000</pubDate>
         <content:encoded><![CDATA[It was clear that San Diego’s MediciNova (NASDAQ: MNOV) had a lot riding on the outcome of a mid-stage trial of the company’s lead drug candidate, bedoradrine sulfate. As I reported recently,...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/lHdRFKmWmgo" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Cytori to Present at the Jefferies 2012 Global Healthcare Conference on June 5</title>
         <link>http://www.marketwire.com/mw/release.do?id=1660493&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 23, 2012) -  Cytori Therapeutics (NASDAQ: CYTX) will present and provide a corporate update from the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 10:00 AM ET. 
        The presentation will ...</description>
         <guid isPermaLink="false" />
         <pubDate>Wed, 23 May 2012 12:00:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 23, 2012) -  Cytori Therapeutics ( NASDAQ : CYTX ) will present and provide a corporate update from the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 10:00 AM ET. </p>
        <p>The presentation will be webcast and may be accessed under "Webcasts" on Cytori's Investor Relations website (<a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=890586&id=1638580&type=1&url=http://ir.cytori.com/">ir.cytori.com</a>). The webcast can be viewed live and will be available for replay after the presentation on the Company's website. </p>
        <p><strong>About Cytori</strong> <br />
        Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family. <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=890586&id=1638583&type=1&url=http://www.cytori.com/">www.cytori.com</a></p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Aegis Therapeutics Awarded Patent for Octreotide Formulations Suitable for Oral and Metered Nasal Spray Delivery</title>
         <link>http://www.marketwire.com/mw/release.do?id=1659405&amp;sourceType=3</link>
         <description>SAN DIEGO, CA--(Marketwire - May 21, 2012) -  Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,133,863 providing broad protection for pharmaceutical composition of octreotide. The highly stable octreotide formulations...</description>
         <guid isPermaLink="false" />
         <pubDate>Mon, 21 May 2012 08:01:00 +0000</pubDate>
         <content:encoded><![CDATA[<div class="mw_release">
 <p>SAN DIEGO, CA--(Marketwire - May 21, 2012) -  Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,133,863 providing broad protection for pharmaceutical composition of octreotide. The highly stable octreotide formulations incorporate Aegis' Intravail®/ProTek® excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection. Intravail® and ProTek® excipients allow for non-invasive delivery with high efficiency. They stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in many protein injectable drugs. </p>
        <p>Octreotide is a peptide hormone that mimics natural somatostatin pharmacologically. Octreotide is used to treat acromegaly, severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide Tumors (VIPomas). </p>
        <p>A published preclinical study conducted at Albany Medical College by Dr. Patricia Grasso demonstrated that formulations of octreotide incorporating Aegis' Intravail®/ProTek® excipients show oral bioavailability that equals or exceeds that achieved by injection*, offering the prospect of a "first in class" non-injectable octreotide. Non-injectable dosage forms of previously injectable-only drugs provide greater patient convenience and acceptance, improved compliance, and avoidance of needle-stick injury and disposal problems associated with the use of needles, paving the way to increased market share and substantial growth in overall product sales. </p>
        <p><strong>About Aegis Therapeutics<br />
        </strong>Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. For more information about Aegis, please visit: <a rel="nofollow" target="_blank" href="http://ctt.marketwire.com/?release=889229&id=1625338&type=1&url=http://www.aegisthera.com/">http://www.aegisthera.com</a>. </p>
        <p>*Regulatory Peptides 167 (2011) 233-238.</p>

          </div>]]></content:encoded>
      </item>
      <item>
         <title>Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/WEhGtsQF4hY/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=190818</guid>
         <pubDate>Mon, 21 May 2012 07:05:10 +0000</pubDate>
         <content:encoded><![CDATA[[Updated: 9:20 pm PT] Only a few companies have ever been successful enough to call themselves Big Biotechs. If boards and shareholders lack vision and guts, we’ll look back in a few years and wonder...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/WEhGtsQF4hY" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>For Those on Watch, Hope Springs Eternal as Hair Trials Inch Along</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/zWcxMNC2lbs/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=190727</guid>
         <pubDate>Fri, 18 May 2012 10:40:55 +0000</pubDate>
         <content:encoded><![CDATA[Waiting for the biotech industry to advance new treatments for male pattern baldness (as well as female hair loss) might seem about as exciting as watching hair grow. But some people have a lot of...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/zWcxMNC2lbs" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>SD Biotech Roundup: Elevation Pharmaceuticals, BioSurplus, and More</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/uat8-oYTteg/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=190553</guid>
         <pubDate>Thu, 17 May 2012 14:04:28 +0000</pubDate>
         <content:encoded><![CDATA[We’re anticipating a lot of news out of a big cancer conference that begins next week in Chicago. Here is your head start. —Cancer researchers have talked for decades about finding the silver bullet...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/uat8-oYTteg" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Xconomist of the Week: Tom Maniatis on Prize4Life and ALS Research</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/zHC7hzss1ZU/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=190444</guid>
         <pubDate>Thu, 17 May 2012 07:50:33 +0000</pubDate>
         <content:encoded><![CDATA[A few years back, molecular geneticist Tom Maniatis was approached by a Harvard Business School student with a heart-wrenching story. The student, Avichai Kremer, then 29, had been diagnosed with...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/zHC7hzss1ZU" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/S24AQWO2vQc/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=190303</guid>
         <pubDate>Wed, 16 May 2012 07:05:05 +0000</pubDate>
         <content:encoded><![CDATA[[Updated: 1:30 pm PT, 5/17/12] One of the big dreams in biotech over the past 35 years has been to make drugs that work like “smart bombs” by destroying tumors while minimizing collateral damage....<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/S24AQWO2vQc" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>ASCO Preview: Eight Cancer Drugs to Watch at the Big Show</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/rcC5HznlXwo/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=190076</guid>
         <pubDate>Mon, 14 May 2012 07:05:58 +0000</pubDate>
         <content:encoded><![CDATA[The pistons of the biggest publicity engine in cancer R&#38;D will start firing this week. It’s time to behold the annual rite of the American Society of Clinical Oncology (ASCO) meeting, the biggest...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/rcC5HznlXwo" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>SD Life Sciences Roundup: Celladon, Vertex, MediciNova, &amp; More</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/f4tTEIpCCws/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189889</guid>
         <pubDate>Thu, 10 May 2012 19:29:00 +0000</pubDate>
         <content:encoded><![CDATA[Massachusetts’ Vertex and San Diego’s Celladon are advancing some promising gene therapy treatments. Here’s our roundup of life sciences news over the past week. —San Diego’s Celladon, which is...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/f4tTEIpCCws" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>A 10-Point Plan to Stimulate Biotech &amp; the Economy as a Whole</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/9o6c55kay8c/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189275</guid>
         <pubDate>Wed, 09 May 2012 08:30:31 +0000</pubDate>
         <content:encoded><![CDATA[AN OPEN LETTER TO PRESIDENT OBAMA Dear President Obama: As you and the rest of our nation’s leadership grapple with the momentous questions of restoring our collective financial stability and...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/9o6c55kay8c" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>San Diego’s MediciNova Nears Turning Point with Lead Drug for Asthma</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/ze7U5O02m5U/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189573</guid>
         <pubDate>Tue, 08 May 2012 19:05:53 +0000</pubDate>
         <content:encoded><![CDATA[[Corrected 5/7/12, 5:10 pm. See below.] When Yuichi Iwaki started MediciNova in 2000, he says many mid-size pharmaceutical companies in Japan had concluded it was just too difficult to conduct their...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/ze7U5O02m5U" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>San Diego’s Celladon Extends Round to $53M, Opens European Office</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/1cSwqLobqpw/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189552</guid>
         <pubDate>Tue, 08 May 2012 15:45:10 +0000</pubDate>
         <content:encoded><![CDATA[San Diego-based Celladon, which raised $43 million in February to advance development of a gene therapy treatment for heart disease, has extended the round with an additional $10 million, according...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/1cSwqLobqpw" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>First Comes The $1,000 genome, Then Comes The $10,000 Analysis</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/sWi9yGDA7d0/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189389</guid>
         <pubDate>Tue, 08 May 2012 08:30:55 +0000</pubDate>
         <content:encoded><![CDATA[While everyone in the in the world of sequencing has heard this cynical joke, as an industry, the joke is about to be on us. We have focused our time, energy and investment on the ability to sequence...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/sWi9yGDA7d0" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Vertex Shares Boom on Cystic Fibrosis Results</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/3OtA2YF0nGk/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189329</guid>
         <pubDate>Mon, 07 May 2012 11:30:39 +0000</pubDate>
         <content:encoded><![CDATA[[Updated: 9:40 am ET] Vertex Pharmaceuticals wowed the cystic fibrosis community earlier this year with its new drug that improves lung function for patients with a rare form of the inherited...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/3OtA2YF0nGk" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Antibiotic R&amp;D is in Trouble: Here’s One Way to Fix It</title>
         <link>http://feedproxy.google.com/~r/Xconomy_San_Diego_Life_Sciences/~3/9CH3z4w1k90/</link>
         <guid isPermaLink="false">http://www.xconomy.com/?p=189336</guid>
         <pubDate>Mon, 07 May 2012 07:02:45 +0000</pubDate>
         <content:encoded><![CDATA[Bacteria have been on Earth for more than a billion years, evolving in crafty ways to stay alive amid all kinds of threats. Only about 70 years ago, antibiotics came along and became one of the great...<br/>
<br/>
[[Click headline to continue reading.]]<img src="http://feeds.feedburner.com/~r/Xconomy_San_Diego_Life_Sciences/~4/9CH3z4w1k90" height="1" width="1"/>]]></content:encoded>
      </item>
      <item>
         <title>Technical Key Account Manager</title>
         <link>http://sdbn.org/2012/05/03/technical-key-account-manager/</link>
         <description>Hiring Company: Microlytic
Job Code: Technical Key Account Manager
Location: San Diego, San Francisco, Boston
Job Type: Sales
Compensation: $ 100,000+
Description: Your primary focus will be the commercialization of Microlytic products into the workflow of a set of key accounts as well as other accounts. Your primary responsibility is to drive sales growth while maintaining existing business within the [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=94042</guid>
         <pubDate>Fri, 04 May 2012 00:00:14 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F05%2F03%2Ftechnical-key-account-manager%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F05%2F03%2Ftechnical-key-account-manager%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Microlytic</p>
<p><b>Job Code</b>: Technical Key Account Manager</p>
<p><b>Location</b>: San Diego, San Francisco, Boston</p>
<p><b>Job Type</b>: Sales</p>
<p><b>Compensation</b>: $ 100,000+</p>
<p><b>Description</b>: Your primary focus will be the commercialization of Microlytic products into the workflow of a set of key accounts as well as other accounts. Your primary responsibility is to drive sales growth while maintaining existing business within the territory, in order to meet or exceed revenue goals. The position will involve significant travel to customer sites, primarily in North America, but from time to time worldwide, as the business may require, to reach our annual sales goals. Your day-to-day activities will focus on on-site meetings with customers, solving their technical problems and facilitating the integration of Microlytic products into their workflow. The ideal candidate will reside in San Diego, Boston, or San Francisco.   </p>
 
ESSENTIAL DUTIES AND RESPONSIBILITIES:
<p>
•	Present product information and discuss crystallography research with customers and prospective customers in your assigned territory.<br />
•	Meet or exceed revenue goals and other goals as assigned.<br />
•	Leverage your technical expertise to meet or exceed your sales targets.<br />
•	Increase our competitive advantage and enhance customer satisfaction<br />
•	Build effective business and collaboration relationships with customers.<br />
•	Prospecting to develop new accounts and arrange sales meetings.<br />
•	Product demonstrations in the field.<br />
•	Develop tactical plans to maximize revenues.<br />
•	Complete and submit sales reports and documentation in a timely and efficient manner.<br />
•	Provide regular reports on customer inquiries, and communicate successes, failures, best practices etc to improve the overall product offering.<br />
•	Present technical seminars in person, via telephone or web conference<br />
•	Gather and report customer and technical information<br />
•	Represent Microlytic at tradeshows/exhibitions and other “on-site” events in order to promote crystallography products and services, receive feedback, network with customers and prospective customers.<br />
•	Monitor competitive landscape and provide analysis of key findings to senior management.<br />
•	This work will entail significant travel to customer sites.</p>
 
QUALIFICATIONS AND EXPERIENCE:
<p>
•	Minimum B.S. degree in life sciences, Ph.D. or M.S. in crystallography preferred.<br />
•	Minimum of 3 years lab experience with proven knowledge and understanding of structural biology, preferably within crystallography.<br />
•	Technical competency to interpret customer’s needs and identify solutions; to stay current in technical knowledge; to troubleshoot and to provide information back to customers in a helpful, courteous, positive and professional manner.<br />
•	Sales experience, and prior success with building and sustaining high growth of sales to pharmaceutical and biotechnology companies, as well as academic and research institutes and federal research agencies, is preferred.<br />
•	Possess a well developed network of customer contacts within the life sciences industry.<br />
•	Ability to navigate through targeted organizations to understand the internal dynamics and the decision-making processes of those companies, and the ability to acquire and learn the information to understand customer’s needs and requirements.<br />
•	Excellent oral and written communication skills.<br />
•	Experience in presenting technical materials in written and verbal form is critical.<br />
•	Strong commitment to customer service and satisfaction.<br />
•	Ability to effectively work on and manage many priorities at one time.<br />
•	A clear and persuasive communication style, with the ability to gain trust and respect and to command attention both externally and internally.<br />
•	A supportive and approachable team player, who is able to challenge in a constructive manner, yet not hesitate to show independent and creative thinking, and be able to compromise in order to accomplish the objective.<br />
•	Must be self-reliant and a self-starter, with an entrepreneurial spirit, who is results oriented, has a sense of urgency, and has a competitive desire to succeed.</p>
 
About Microlytic:
<p>
Founded in 2006, Microlytic is an innovator and commercial provider of consumable laboratory products for the structural biology marketplace. Our mission is to provide a portfolio of innovative products that simplify the workflow, increase productivity and offer an attractive economic value proposition to our customers. For more information about Microlytic, please visit http://www.microlytic.com.
</p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.microlytic.com/careers">http://www.microlytic.com/careers</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>Scientist</title>
         <link>http://sdbn.org/2012/04/05/scientist-2/</link>
         <description>Hiring Company: Aerotek
Location: San Diego
Compensation: $ 80-110k
Description: Description:
A Scientist to work in a dynamic, team-oriented environment and help create genomic analysis tools used in the leading edge of research. You will work with multi-disciplinary teams to create cutting edge and robust new products and assays for the next generation sequencing platforms. You will participate in [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=93632</guid>
         <pubDate>Thu, 05 Apr 2012 21:35:26 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F04%2F05%2Fscientist-2%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F04%2F05%2Fscientist-2%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Aerotek</p>
<p><b>Location</b>: San Diego</p>
<p><b>Compensation</b>: $ 80-110k</p>
<p><b>Description</b>: Description:<br />
A Scientist to work in a dynamic, team-oriented environment and help create genomic analysis tools used in the leading edge of research. You will work with multi-disciplinary teams to create cutting edge and robust new products and assays for the next generation sequencing platforms. You will participate in the development of new platforms for arrays and sequencing.</p>
<p>Responsibilities:<br />
• Develop new products in fast-paced product development environment</p>
<p>• Identify, evaluate, plan, and optimize research ideas leading to new robust assays for DNA and RNA based on proprietary technologies</p>
<p>• Explore new technologies and identify creative solutions to overcome current limitations</p>
<p>• Design, implement, analyze and present experiments to demonstrate feasibility of new methods and efficiently move products through pipeline</p>
<p>• Optimize assay conditions to achieve commercial levels of stability, robustness, and performance</p>
<p>• Create scalable infrastructure to support release of developed products</p>
<p>• Be both a strong individual contributor as well as a collaborative team member. Conduct clear and concise communication with colleagues (cross-functional) and supervisors through oral updates, written reports and technical meetings</p>
<p>Education and Experience:<br />
• Ph. D. in the chemistry or biochemistry with greater than 3 years of industrial experience<br />
• Strong background in surface chemistry, biochemistry and enzymology and a sound understanding of assay development required<br />
• Experience with next-generation sequencing methods helpful. Skilled in analysis of large and complex data sets<br />
• Must be detail oriented and highly motivated.</p>
<p>This position is temporary at least through the end of the year. There is a possibility of it going permanent at some point.</p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.aerotek.com">http://www.aerotek.com</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>Brewing Science: Improving Science Communication with ASBMB April 23rd At Mission Brewery</title>
         <link>http://sdbn.org/2012/03/30/brewing-science-improving-science-communication-with-asbmb-april-23rd-at-mission-brewery/</link>
         <description>In April we&amp;#8217;re teaming up with the American Society for Biochemistry and Molecular Biology (ASBMB) to host an event at Mission Brewery downtown during the big Experimental Biology conference. You may know we are big proponents of science communication because it helps researchers with their careers, funding, and connecting with other scientists.
The event will feature [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=93532</guid>
         <pubDate>Fri, 30 Mar 2012 17:08:11 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F30%2Fbrewing-science-improving-science-communication-with-asbmb-april-23rd-at-mission-brewery%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F30%2Fbrewing-science-improving-science-communication-with-asbmb-april-23rd-at-mission-brewery%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><a rel="nofollow" target="_blank" href="http://sdbn.org/wp-content/uploads/2012/03/brewingscience1_lg.jpg"><img src="http://sdbn.org/wp-content/uploads/2012/03/brewingscience2_sm.jpg" alt="" title="Brewing Science: Improving Science Communication with ASBMB April 23rd At Mission Brewery" width="250" class="alignright"/></a>In April we&#8217;re teaming up with the <a rel="nofollow" target="_blank" href="http://www.asbmb.org/News.aspx?id=16163">American Society for Biochemistry and Molecular Biology (ASBMB)</a> to host an event at Mission Brewery downtown during the big <a rel="nofollow" target="_blank" href="http://experimentalbiology.org/EB/pages/default.aspx?splashpage=1">Experimental Biology conference</a>. You may know we are big proponents of science communication because it helps researchers with their careers, funding, and connecting with other scientists.</p>
<p>The event will feature bloggers, reporters, industry professionals, public speaking experts, and policy makers, all who will be available to help you improve your science communication skills. We&#8217;ll have some fun contests to help you meet people, and there will be appetizers and drinks available for purchase as well (we hope to be able to give drink tickets depending on sponsorship, stay tuned&#8230;).</p>
<p>We&#8217;ll have discussions on blogs and Twitter leading up to the event so that you can participate, connect, and get the most out of the event. Follow <a rel="nofollow" target="_blank" href="https://twitter.com/#!/search/%23eb2012tweetup">#eb2012Tweetup</a> and see <a rel="nofollow" target="_blank" href="http://www.asbmb.org/News.aspx?id=16163">the list of science communicators participating here.</a> If you&#8217;re a blogger, we&#8217;re asking you to write a post describing your science communication success stories and <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">submit them here</a> or tag them on Twitter with #eb2012Tweetup. For example, did you get funding or make an important connection or discovery through a new type of science communication? We&#8217;ll post links to the blog posts here and send a weekly email update. We&#8217;re hoping everyone will be inspired to communicate science in new ways.</p>
<p>Note: The word cloud featured in the image for this post is from 5,000 Twitter status updates tagged with <a rel="nofollow" target="_blank" href="https://twitter.com/#!/search/%23scicomm">#scicomm</a>, the ongoing discussion about science communication on Twitter. If you&#8217;d like to see more detail, click on the image to enlarge it.</p>
<h3>Sponsors</h3>
<table border="0">
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.neb.com"><img src="http://sdbn.org/wp-content/uploads/2012/03/NEB_Color_hi-res1-300x116.jpg" alt="" title="New England BioLabs" width="250" class="alignnone size-medium wp-image-93603"/></a></td>
<td><a rel="nofollow" target="_blank" href="http://www.mendeley.com"><img src="http://sdbn.org/wp-content/uploads/2012/03/horizontal_full_color-300x73.png" alt="" title="Mendeley" width="300" class="alignnone size-medium wp-image-93661"/></a></td>
</tr>
</table>
<p><br/>We&#8217;re expecting this event to draw at least 200 life science researchers and professionals, and this event will be advertised at the Experimental Biology conference, <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">contact us</a> for sponsorship opportunities.</p>
<h3>Event Details</h3>
<p><strong>Who:</strong> Life science researchers and professionals in the greater San Diego area<br />
<strong>What:</strong> Brewing Science: Improving Science Communication with ASBMB<br />
<strong>When:</strong> Monday, April 23rd 2012, 7:30-9:30 p.m.<br />
<strong>Where:</strong> Mission Brewery,1441 L Street, San Diego Ca 92101 (Directions below)<br />
<strong>Cost: </strong>$15/10 (Academic), appetizers provided, beverages for purchase (Mission Brewery beers on tap, soda), complimentary water. Free for 2012 Experimental Biology attendees, wear your badge.<br />
<strong>Contact:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">http://sdbn.org/contact</a><br />
<strong>For more information about the event:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/scicomm">http://sdbn.org/scicomm</a><br />
<a rel="nofollow" target="_blank" href="http://sdbn.org/register"><img class="alignright size-medium wp-image-534" title="Register" src="http://sdbn.org/wp-content/uploads/2008/10/sdbnbutton_24.jpg" alt="" width="150" height="77"/></a><br />
<strong>Directions:</strong> <em>Driving:</em> Exit the 5 south at Imperial, take a right on Imperial, travel 2 blocks to 14th street, take a right and  Mission Brewery is at 14th &#038; L on the right, you can park in one of the ballpark lots (there won&#8217;t be a game that night) or on the street. <em>Walking from the convention center:</em> Take a right when exiting the convention center front doors, heading southeast along Harbor Drive. Cross over Park Blvd and take the footbridge on the left. Continue along the sidewalk until you hit the light at 10th street, then take a right, walking through the parking lot. You&#8217;ll see the sign for Mission Brewery ahead on the right, it&#8217;s a brick building and hard to miss. The walk should take 10 minutes. While the neighborhood is not that bad, we suggest walking back to the gaslamp in groups after the event.</p>]]></content:encoded>
      </item>
      <item>
         <title>Medical Director</title>
         <link>http://sdbn.org/2012/03/26/medical-director/</link>
         <description>Hiring Company: Sanford Rose Associates &amp;#8211; San Diego
Location: Chula Vista, CA
Job Type: Regular/Full-Time
Description: The ideal candidate will have the following background and experience:
•	MD Board Certified in Internal Medicine with additional training in Endocrinology and Metabolism and/or Cardiology preferred. Candidates with experience in other therapeutic areas with strong backgrounds in clinical research will be considered.
•	An unrestricted [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=93451</guid>
         <pubDate>Mon, 26 Mar 2012 22:49:33 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F26%2Fmedical-director%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F26%2Fmedical-director%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Sanford Rose Associates &#8211; San Diego</p>
<p><b>Location</b>: Chula Vista, CA</p>
<p><b>Job Type</b>: Regular/Full-Time</p>
<p><b>Description</b>: The ideal candidate will have the following background and experience:</p>
<p>•	MD Board Certified in Internal Medicine with additional training in Endocrinology and Metabolism and/or Cardiology preferred. Candidates with experience in other therapeutic areas with strong backgrounds in clinical research will be considered.<br />
•	An unrestricted license to practice medicine in California (or eligibility) is required.<br />
•	Minimum of (2+) years of clinical research experience as a physician conducting clinical trials within the pharmaceutical industry, a clinical research organization, or as an Assistant/ Associate Professor of Internal Medicine in academic research.<br />
•	An understanding of clinical pharmacology principles of drug development and strong clinical skills are essential, as is an interest in science and research.
</p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://sanfordrose.com/sandiego/">http://sanfordrose.com/sandiego/</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>San Diego’s Biotechnology Companies: Who’s Taking Off?</title>
         <link>http://sdbn.org/2012/03/08/san-diegos-biotechnology-companies-whos-taking-off/</link>
         <description>Image Courtesy Flickr User JoFHere at SDBN we’ve been updating our directory of 400+ San Diego biotech companies.  We were surprised to find close to 40 companies removed from the local scene – due to acquisition or shut down.  But we also found a net gain in companies, with 68 added.  We&amp;#8217;ve begun to [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=93005</guid>
         <pubDate>Thu, 08 Mar 2012 16:13:49 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F08%2Fsan-diegos-biotechnology-companies-whos-taking-off%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F08%2Fsan-diegos-biotechnology-companies-whos-taking-off%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><div id="attachment_93184" class="wp-caption alignright" style="width:250px;"><a rel="nofollow" target="_blank" href="http://www.flickr.com/photos/jof/214775481/"><img src="http://sdbn.org/wp-content/uploads/2012/03/Torrey_pines.jpg" alt="" title="La Jolla Torrey Pines Life Science Cluster" width="240" height="230" class="size-full wp-image-93184"/></a><p class="wp-caption-text">Image Courtesy Flickr User JoF</p></div>Here at SDBN we’ve been updating our <a rel="nofollow" target="_blank" href="http://sdbn.org/directory">directory of 400+ San Diego biotech companies</a>.  We were surprised to find close to 40 companies removed from the local scene – due to acquisition or shut down.  But we also found a net gain in companies, with 68 added.  We&#8217;ve begun to add some of the &#8216;provenances&#8217; of new companies, as well as what&#8217;s happened to those that are no longer listed, and welcome your comments and additions as well, please leave them as a comment below. Note that some companies are not new, we just missed them in our original directory and wanted to feature them in this post.
<h3>Updates to San Diego Biotechnology Company Directory</h3>
<table class="payment" width="550">
<tr>
<th>Company</th>
<th>Status</th>
<th>Details</th>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://1060de.com/	">	1060 Discovery Engineering	</a></td>
<td>	Added	</td>
<td>		</td>
</tr>
<tr>
<td>	Adnavance	</td>
<td>	Removed	</td>
<td>		</td>
</tr>
<tr>
<td>	ALARIS Medical Systems	</td>
<td>	Removed	</td>
<td>	Now under Cardinal Health	</td>
</tr>
<tr>
<td>	<a rel="nofollow" target="_blank" href="http://www.alere.com/">Alere</a>	</td>
<td>	Added	</td>
<td>	Acquired Biosite </td>
</tr>
<tr>
<td>	Altair Therapeutics	</td>
<td>	Removed	</td>
<td>	Shut down	</td>
</tr>
<tr>
<td>	Amira Pharmaceuticals 	</td>
<td>	Removed	</td>
<td>	Acquired by Bristol-Myers Squibb 	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://amplyx.com/">	Amplyx Pharmaceuticals</a> 	</td>
<td>	Added </td>
<td>	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.aperio.com/default.asp 	">	Aperio 	</a></td>
<td>	Added	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.appliedproteomics.com	">	Applied Proteomics 	</a></td>
<td>	Added	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.aragonpharm.com	">	Aragon Pharmaceutical	</a></td>
<td>	Added 	</td>
<td> </td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.astutemedical.com/	">	Astute Medical 	</a></td>
<td>	Added 	</td>
<td>	BioSite spinoff	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.avantgen.com/index.html 	">	AvantGen 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.avelasbio.com 	">	Avelas Biosciences 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.azcobiotech.com 	">	Azco Biotech, Inc. 	</a></td>
<td>	Added	</td>
<td>		</td>
</tr>
<tr>
<td>	Balboa Bio 	</td>
<td>	Removed	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.batj.net/	">	Bio Applied Technologies Joint, Inc. 	</a></td>
<td>	Added	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.bioatla.com/index.html 	">	BioAtla 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://biocept.com	">	Biocept 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.biolaurus.com	">	BioLaurus 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	BioMedica, Inc. 	</td>
<td>	Removed	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://biosettia.com	">	BioSettia 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>BioSite 	</td>
<td>	Removed </td>
<td>Acquired by Alere</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.biotixinc.com/Default.aspx 	">	Biotix	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.bpsbioscience.com 	">	BPS Bioscience, Inc 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Calmune Corporation 	</td>
<td>	Removed	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.carolustherapeutics.com/index.html 	">	Carolus Therapeutics 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.cebix.com 	">	Cebix 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://crinetics.com/Welcome.html 	">	Crinetics 	</a></td>
<td>	Added 	</td>
<td>Started by ex-Neurocrine employees</td>
</tr>
<tr>
<td>	CryoCor, Inc. 	</td>
<td>	Removed	</td>
<td>		</td>
</tr>
<tr>
<td>	Diverse Diagnostics 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	Dx Innovations 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://elcelyx.com/ 	">	Elcelyx 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.enigmadiagnostics.com/index.php 	">	Enigma diagnostics 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://essentialistherapeutics.com 	">	Essentialis 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.etaluma.com 	">	Etaluma 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.eumederis.com/home 	">	EuMederis Pharmaceuticals, Inc. 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.expedeon.com">	Expedeon 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.genetex.com 	">	Genetex 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://genofi.com/index.asp 	">	Genofi 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.gentarget.com 	">	GenTarget Inc, 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.genvault.com 	">	GenVault 	</a></td>
<td>	Added 	</td>
<td>	Existing, missed in original directory	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.harbortx.com Used to be Hollis-Eden, name change 	">	Harbor Biosciences 	</a></td>
<td>	Added 	</td>
<td>	Changed name from Hollis Eden	</td>
</tr>
<tr>
<td>	Helixis	</td>
<td>	Removed	</td>
<td>	Acquired by Illumina	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.hemaquest.com 	">	HemaQuest 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Hollis-Eden 	</td>
<td>	Removed 	</td>
<td>	Changed name to Harbor Biosciences 	</td>
</tr>
<tr>
<td>	Iapyx Medical 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	Icx Biosystems 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	IDM Pharma, Inc. 	</td>
<td>	Removed 	</td>
<td>	Acquired by Takeda 2009 	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.inceptionsci.com/	">	Inception Sciences	</a></td>
<td>	Added	</td>
<td>	Amira spinoff	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.inhibrx.com 	">	Inhibrx 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	KFx Medical, Inc. 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.kinagen.com/home.htm 	">	Kinagen, Inc. 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Kinexis, Inc. 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://kyowa-kirin-ca.com/contact_us.cfm 	">	Kyowa Hakko Kirin California, Inc. 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://legenebiosciences.com 	">	LeGene Biosciences 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.liquidgrids.com/	">	LiquidGrids	</a></td>
<td>	Added	</td>
<td>	Previously known as Swarmology	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.mabprex.com 	">	MabPrex.com 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	MediVas LLC 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	Metabasis Therapeutics, Inc. 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.mobio.com 	">	MO BIO Laboratories	</a></td>
<td>	Added 	</td>
<td>	Existing company missed in original directory	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://molecularresponse.com 	">	Molecular Response 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Mpex Pharmaceuticals 	</td>
<td>	Removed 	</td>
<td>Name change to Rempex</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://nacalaiusa.com 	">	Nacalai usa 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	NeoMPS, Inc. 	</td>
<td>	Removed 	</td>
<td>	Now part of PolyPeptide Group 	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.neurogeneticpharmaceuticals.com 	">	NeuroGenetic Pharmaceuticals Inc. 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Novalar 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	Nventa	</td>
<td>	Removed 	</td>
<td>	Merger with Akela Pharma, Inc March 27, 2008 	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://oceansidepharma.com 	">	Oceanside Pharmacuticals 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Orbigen 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	ORQIS Medical Corporation 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	PAGEgel, Inc. 	</td>
<td>	Removed 	</td>
<td>	Merged with Expedeon/Protein Discovery 	</td>
</tr>
<tr>
<td>	Paramount BioSciences, LLC 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.pegasuscleanroom.com 	">	Pegasus Cleanroom Services 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Perry Scientific 	</td>
<td>	Removed 	</td>
<td>	Acquired by Absorption Systems 	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.pfenex.com/content/index.php 	">	Pfenex 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://pharmacircle.com 	">	PharmaCircle 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.phenometricsinc.com/index.html 	">	Phenometrics 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Phenomix 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://plicarerx.com 	">	PliCare Therapeutics 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://proteinlabs.com/index.htm 	">	ProteinLabs 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.rebexsess.com 	">	Rebexsess 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.rempexpharma.com 	">	Rempex Pharmaceuticals 	</a></td>
<td>	Added 	</td>
<td>	Name change from Mpex	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.renascions.com 	">	Renascions 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.seaspine.com 	">	SeaSpine 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.serametrix.com 	">	Serametrix 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.sgbiofuels.com/index.php 	">	SG Biofuels 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	SGX Pharmaceuticals, Inc. 	</td>
<td>	Removed 	</td>
<td>	As of 2008, acting as subsidiary of Lilly 	</td>
</tr>
<tr>
<td>	Sidney Kimmel Cancer Center 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.sonexa.com/index.html 	">	Sonexa Therapeutics 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.sorrentotherapeutics.com/index.php 	">	SorrentoTherapeutics.com 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.sovapharma.com/company.html 	">	Sova Pharmaceuticals 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.stratbiocat.com/index.html 	">	Strategic Enzyme Applications 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Tanox 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	TargeGen, Inc. 	</td>
<td>	Removed 	</td>
<td>	Acquired by Sanofi-Aventis 	</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.targeson.com 	">	Targeson Inc 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://theragence.com/Theragence/Theragence_Inc.html 	">	Theragence Inc. 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	TheraKem 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	Torrey Path, LLC 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	TorreyPines Therapeutics 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://trovagene.com/Welcome.html 	">	TrovaGene 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Tulip BioMed, Inc. 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.ultimatelab.com Partnered with Diverse Diagnostics in 2008	">	Ultimate Labs 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td>	Vasgene 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td>	Verus Pharmaceuticals, Inc 	</td>
<td>	Removed 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.viacyte.com 	">	ViaCyte Technologies: Stem Cell Engineering 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://vivamab.com 	">	VivaMab, LLC 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.westwirelesshealth.org	">	West Wireless Health Institute	</a></td>
<td>	Added	</td>
<td>		</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="	http://www.zacharon.com/company.html 	">	Zacharon Pharmaceuticals 	</a></td>
<td>	Added 	</td>
<td>		</td>
</tr>
</table>
<p>
A recent report suggests evidence that the San Diego biotech scene is going strong.  Released in December 2011 the <em>Life Sciences Cluster Report</em> by Jones Lang LaSalle rates San Diego #7 in the global biotech clusters.  The report examines global locations for viable industry hubs, and defines a “cluster” by a multiple data points including:</p>
<ul>
<li>Educated workforce</li>
<li>Venture and investment capital</li>
<li>Centers of excellence and innovation</li>
<li>Industry-friendly political structures</li>
<li>Institutions of higher learning</li>
<li>Target economic development incentives</li>
<li>Patent protection</li>
<li>Other associations and supporting infrastructure</li>
</ul>
<p>Ranking in the top 10 for funding &#8211; third in VC and sixth for NIH funding &#8211; it seems that the money is rolling in for San Diego. The 97-page study says San Diego’s dense concentration of incubator and start-ups is expected to continue growth in the near future.</p>
<p>Each of the submarkets reviewed – UTC, Torrey Pines, Sorrento Mesa, and Sorrento Valley – experienced growth in 2011, aside from Sorrento Mesa being almost completely leased.  The report forecasts continued recovery in rents, vacancies tightening and, due to a lack of new development, re-positioning of older properties to meet demands for higher quality facilities, particularly in Sorrento Mesa.</p>
<p>Additionally, Torrey Pines, San Diego’s largest submarket, has seen a resurgence of growth, with more life science companies acquiring larger spaces. The report states that in 2011 Verenium signed a deal larger than Torrey Pines has seen in two years.</p>
<p>NIH grants have increased 28 percent from 2010 and by 70 percent from 2008.  The outlook is sunny for San Diego in 2012, with a continued increase expected in the number of start-ups and dispersal of capital from venture capital and government funds.</p>
<p>A PDF of the complete report can be <a rel="nofollow" target="_blank" href="http://www.joneslanglasalle.com/ResearchLevel1/Global_Life%20Sciences%20Cluster%20Report_2011_gb.pdf">downloaded here</a>.</p>
<p>Thanks to Flickr user JoF for <a rel="nofollow" target="_blank" href="http://www.flickr.com/photos/jof/214775481/">this image</a> of gliders taking off and landing at Torrey Pines, where many San Diego life science companies also &#8216;take off.&#8217;</p>]]></content:encoded>
      </item>
      <item>
         <title>SDBN March 26th 2012 Event with Organovo</title>
         <link>http://sdbn.org/2012/03/06/sdbn-march-26th-2012-event-with-organovo/</link>
         <description>Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been included in the MIT Technology Review&amp;#8217;s 2012 TR50 list of the world&amp;#8217;s most innovative companies. The excitement around Organovo has [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=93138</guid>
         <pubDate>Tue, 06 Mar 2012 20:59:27 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F06%2Fsdbn-march-26th-2012-event-with-organovo%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F03%2F06%2Fsdbn-march-26th-2012-event-with-organovo%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><a rel="nofollow" target="_blank" href="http://www.organovo.com/"><img src="http://sdbn.org/wp-content/uploads/2012/03/organovo.jpg" alt="" title="organovo" width="211" height="42" class="alignright size-full wp-image-93141"/></a>Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been included in the MIT Technology Review&#8217;s <a rel="nofollow" target="_blank" href="http://www.technologyreview.com/tr50/2012/">2012 TR50</a> list of the world&#8217;s most innovative companies. The excitement around Organovo has grown since they recently announced funding and their stock is <a rel="nofollow" target="_blank" href="http://www.xconomy.com/san-diego/2012/02/14/organovo-raises-6-5m-lists-on-otc-in-alternative-public-offering/">now publicly traded</a>. You&#8217;ll get the chance to hear from CEO <a rel="nofollow" target="_blank" href="http://sdbn.org/bio-keith-murphy/">Keith Murphy</a> at our March 26th event, he&#8217;ll give a presentation titled &#8216;<em>3D Bioprinting &#8211; Delivering Tissue on Demand for Drug Discovery &#038; Development</em>.&#8217;</p>
<p><strong>At this event, we will delve into innovation and how it happens. </strong> What does it take to make an outstanding product – a game changer?  We all have ideas but how does an idea get to be a reality?  What are the barriers to innovation?  It’s not just time, money and people.  It’s even how you think about the problem.</p>
<p>We have two companies that are innovating to success:</p>
<p><strong>Organovo</strong>, the featured company, will discuss how they overcame barriers to achieve an industry changing technology that still seems futuristic and impossible – printing tissue.<br />
<strong><br />
Invetech</strong>, the event sponsor, helps people translate their ideas into products.  They will share a few key learnings of how to approach innovation.</p>
<p>We want to hear from the local innovators at this event,<br />
-	Do you have an idea but are stuck?<br />
-	How have you been successful in innovation?<br />
-	What barriers are in your way?</p>
<p>We&#8217;re having a contest to see who has the best idea for improving innovation in San Diego. During registration, or on LinkedIn or Twitter (tag with #Invetech), complete this statement: <strong>&#8220;My innovation idea is ______.&#8221;</strong> It can be a product idea or a general idea to improve the innovation culture in San Diego. <strong>We&#8217;ll discuss and vote on the best idea for innovation at the event and the winner will get two free passes to an SDBN event and a $15 gift card to Green Flash Brewery.</strong></p>
<h3>Sponsors</h3>
<h4><strong>Premier</strong></h4>
<table>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.invetech.com.au/"><img src="http://sdbn.org/wp-content/uploads/2012/03/INVETECH-LOGO.jpg" alt="" title="Invetech" width="350" height="63" class="alignright size-full wp-image-93249"/></a></td>
</tr>
</table>
<p><span style="font-size:0.7em;font-style:italic;line-height:110%;">Invetech is a contract product development and manufacturing consultancy working with companies worldwide. We provide a range of instrument, medical device and consumables development and manufacturing services that develop break-through products and solve complex automation challenges. With over 200 in-house specialists and experience drawn from over 5,000 projects, we work with medical device, clinical diagnostics, life sciences and drug discovery companies. Operating from locations in North America, Europe and Asia Pacific, our clients range from start-ups through to multinationals. Our proven design, engineering and manufacturing processes deliver shorter time-to-market, reduced risk, and enhanced product quality.</span><br />
If you&#8217;re interested in sponsoring this event, please <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">contact us</a>.</p>
<h3>Event Details</h3>
<p><strong>Who:</strong> Biotechnology professionals in the greater San Diego area<br />
<strong>What:</strong> SDBN March 26th Event with Organovo<br />
<strong>When:</strong> Monday, March 26th 2012, 5:30-8:30 p.m.<br />
<strong>Where:</strong> Green Flash Tasting Room, 6550 Mira Mesa Boulevard, San Diego, CA 92121 (Directions below)<br />
<strong>Cost: </strong>$25/20 (Academic), dinner provided, beverages for purchase (30 Green Flash beers on tap, soda), complimentary water.<br />
<strong>Contact:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">http://sdbn.org/contact</a><br />
<strong>For more information about the event:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/marchevent">http://sdbn.org/marchevent</a><br />
<a rel="nofollow" target="_blank" href="http://sdbn.org/register"><img class="alignright size-medium wp-image-534" title="Register" src="http://sdbn.org/wp-content/uploads/2008/10/sdbnbutton_24.jpg" alt="" width="150" height="77"/></a><br />
<strong>Directions:</strong> From the west: From the 805 North or South exit Mira Mesa Blvd, head east for 2.0 miles, the Green Flash Tasting Room will be on the left/north side of the street at Flanders Drive. From the east: From the 15 North or South exit Mira Mesa Blvd, head west for 3.6 miles, the Green Flash Tasting Room will be on the right/north side of the street at Flanders Drive.<br />
<strong>Parking:</strong> The Green Flash lot holds about 70 cars, so come early and carpool if you&#8217;d like to park there. You can also park on the street, but <strong>be very mindful that there are some poorly marked &#8216;no parking&#8217; areas, especially on Sequence where there is a center lane.</strong></p>]]></content:encoded>
      </item>
      <item>
         <title>Building &amp; Leveraging Life Science Networks</title>
         <link>http://sdbn.org/2012/02/24/lifesciencenetwork/</link>
         <description>Building &amp;#38; Leveraging Life Science Networks 
 View more from author Mary Canady or schedule a free consultation.</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92922</guid>
         <pubDate>Sat, 25 Feb 2012 00:52:02 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F02%2F24%2Flifesciencenetwork%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F02%2F24%2Flifesciencenetwork%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<div style="width:425px;" id="__ss_11740689"> <strong style="display:block;margin:12px 0 4px;"><a rel="nofollow" target="_blank" href="http://www.slideshare.net/marycanady/building-leveraging-life-science-networks" title="Building &amp; Leveraging Life Science Networks">Building &amp; Leveraging Life Science Networks</a></strong> 
<div style="padding:5px 0 12px;"> View more from author <a rel="nofollow" target="_blank" href="http://www.slideshare.net/marycanady">Mary Canady</a> or <a rel="nofollow" target="_blank" href="http://comprendia.com/about/contact/consultation/">schedule a free consultation</a>.</div>
</div>]]></content:encoded>
      </item>
      <item>
         <title>Getting a Scientist’s Attention at #SLAS2012</title>
         <link>http://sdbn.org/2012/02/14/getting-a-scientists-attention-at-slas2012/</link>
         <description>Now that SLAS 2012 has wrapped up, the question is, amid all of those robotic arms, who truly stood out?  We saw some great examples of vendors who were able to draw the crowds, while showcasing some pretty cool technology.
Here’s a list of some great ways to get a scientist’s attention, wonderfully demonstrated by [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92780</guid>
         <pubDate>Tue, 14 Feb 2012 23:58:25 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F02%2F14%2Fgetting-a-scientists-attention-at-slas2012%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F02%2F14%2Fgetting-a-scientists-attention-at-slas2012%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><a rel="nofollow" target="_blank" href="http://sdbn.org/wp-content/uploads/2012/02/Clippard-air-guitar-purple-cropped.jpg"><img class="alignright size-full wp-image-92769" title="Clippard-air-guitar-purple-cropped" src="http://sdbn.org/wp-content/uploads/2012/02/Clippard-air-guitar-purple-cropped.jpg" alt="sdbn, san diego biotechnology network, slas, society for laboratory automation" width="240"/></a>Now that SLAS 2012 has wrapped up, the question is, amid all of those robotic arms, who truly stood out?  We saw some great examples of vendors who were able to draw the crowds, while showcasing some pretty cool technology.</p>
<p>Here’s a list of some great ways to get a scientist’s attention, wonderfully demonstrated by three life science vendors at SLAS 2012.</p>
<ol>
<li><strong>Creativity counts. </strong>Rather than a bunch of cylinders and valves scattered about with some brochures on a table, Clippard center-staged an Air Guitar, rigged to be played.  How does this awesome display work?  Through 62 miniature air cylinders, and 58 valves to control those cylinders that can play each string individually or by strumming all six strings at once.  &#8221;Playing songs that are impossible by the human hand,&#8221; says Rob Clippard from <a rel="nofollow" target="_blank" href="http://www.clippard.com/">Clippard Instrument Laboratory Inc.</a>,&#8221;the controls are as up to date as the idea itself.&#8221;  The iPad app &#8220;Pianist&#8221; plays the song, sends it via midi protocol to a translator board, and tells the miniature pneumatic, low wattage Clippard valves to turn on and off at the right times and move the appropriate cylinder with 50 psi of air.  Did you get all that? That&#8217;s ok &#8211; the guitar is cool, the technology and idea are innovative and unique, and you can learn all about what they have to offer once you&#8217;ve been hooked.  <a rel="nofollow" target="_blank" href="http://youtu.be/8pdjxWmwMdU">Here&#8217;s a video </a>of the Air Guitar in action.</li>
<li><strong>Product? What Product? </strong>Though I have a soft spot in my heart for robotics and laboratory automation, as a recent defector from a Drug Discovery lab, even I can glaze over a bit after the 10<sup>th</sup> or 11<sup>th</sup> robotic arm display.  But, I loved how <a rel="nofollow" target="_blank" href="http://www.home.agilent.com/agilent/home.jspx?cc=US&amp;lc=eng">Agilent</a> showcased their nimble technology, by bringing a bit of Vegas to SLAS.  The pull to stay at the booth was not only the cheering crowd encircling the game, but the fact that as soon as you step into the booth, you receive a poker chip.  An invitation to have some fun, and no need to talk to a rep first?  You got me. After hours of wandering the aisles a distraction is highly welcome.  Odds that someone will remain in your booth for a bit are good at this point, and I did as soon as that chip hit my hand.  Microtiter plates covered with playing cards lined the stacker.  Agilent’s Direct Drive Robotic arm swiftly dealt three people their hands of 21, amid cheering scientists waiting their turn.  After the game, the robot dealer gave you a microtiter “card” that informed you of your prize.  For the sake of some great word of mouth for Agilent, I hope that what happens at SLAS doesn’t stay at SLAS…?</li>
<li><strong>Tap into competition. </strong>Though a large sign announced <a rel="nofollow" target="_blank" href="http://www.artel-usa.com/">Artel&#8217;s</a> Pipetting Olympics (grand prize iPad2!), what caught my eye as I strolled past, were scientists super – super – into pipetting.  And a line of them waiting their turn.  Pipetting?  Ok, I knew it must be worth my wait &#8211;  without even knowing what I was lining up for, I was there with bells on.  All of this was to showcase their calibration and volume verification systems, which they did well.  Scientists were excited, engaged, and most importantly, listening to the reps explain how the system works and how it can work for <em>them</em>.</li>
</ol>
<p>We hope to see even more engaging tactics by vendors as they continue reaching out to all aspects of a scientist&#8217;s interests.  Thanks for a great conference and see you next year!</p>
<p>&nbsp;</p>]]></content:encoded>
      </item>
      <item>
         <title>SDBN February 21st Free Happy Hour: Learning to Leverage Networks</title>
         <link>http://sdbn.org/2012/02/08/sdbn-february-21st-free-happy-hour-learn-to-leverage-your-networks/</link>
         <description>The SDBN group continues to grow rapidly, with about 6,000 members on LinkedIn, thousands more on Facebook and Twitter, and more than 1,000 biotech professionals attending our events each year. How can you leverage the network and your geographic advantage of being in San Diego? Come to our free happy hour February 21st at Green [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92694</guid>
         <pubDate>Wed, 08 Feb 2012 18:50:42 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F02%2F08%2Fsdbn-february-21st-free-happy-hour-learn-to-leverage-your-networks%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F02%2F08%2Fsdbn-february-21st-free-happy-hour-learn-to-leverage-your-networks%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><img src="http://sdbn.org/wp-content/uploads/2012/02/seesaw_world_dreamstime.jpg" alt="" title="life science networking" width="240" height="180" class="alignright size-full wp-image-92695"/>The SDBN group continues to grow rapidly, with about 6,000 members on <a rel="nofollow" target="_blank" href="http://tinyurl.com/sdbiotech">LinkedIn</a>, thousands more on <a rel="nofollow" target="_blank" href="http://facebook.com/sdbiotech">Facebook</a> and <a rel="nofollow" target="_blank" href="http://twitter.com/sdbn">Twitter</a>, and more than 1,000 biotech professionals attending our events each year. How can you leverage the network and your geographic advantage of <a rel="nofollow" target="_blank" href="http://sdbn.org/2012/01/31/focus-on-san-diego-life-science-conferences-spring-2012/">being in San Diego</a>? Come to our free happy hour February 21st at Green Flash Brewery and you&#8217;ll be able to learn from the Comprendia team about how you can leverage networks and tools to advance your career and business. As usual, we&#8217;ll also be open to your suggestions for improving the SDBN. We&#8217;ll be circulating with iPads, and if you&#8217;re just there to socialize, that&#8217;s OK too, there will be many biotech professionals for you to meet.</p>
<h3>Sponsor</h3>
<table>
<tr>
<td><a rel="nofollow" target="_blank" href="http://comprendia.com"><img alt="" src="http://comprendia.com/wp-content/themes/white-as-milk-10/images/comprendia.jpg" title="Life science marketing and social media" class="alignleft" width="250" height="95"/></a></td>
</tr>
</table>
<h3>Event Details</h3>
<p><strong>Who:</strong> Biotechnology professionals in the greater San Diego area<br />
<strong>What:</strong> SDBN February 21st Networking Event<br />
<strong>When:</strong> Tuesday, February 21st 2012, 5:30-8:30 p.m.<br />
<strong>Where:</strong> Green Flash Tasting Room, 6550 Mira Mesa Boulevard, San Diego, CA 92121 (Directions below)<br />
<strong>Cost: </strong>Free, food available for purchase from TBD gourmet food truck, beverages available for purchase (30 Green Flash beers on tap, soda, complimentary water).<br />
<strong>Contact:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">http://sdbn.org/contact</a><br />
<strong>For more information about the event:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/february">http://sdbn.org/february</a><br />
<a rel="nofollow" target="_blank" href="http://sdbn.org/register"><img class="alignright size-medium wp-image-534" title="Register" src="http://sdbn.org/wp-content/uploads/2008/10/sdbnbutton_24.jpg" alt="" width="150" height="77"/></a><br />
<strong>Directions:</strong> From the west: From the 805 North or South exit Mira Mesa Blvd, head east for 2.0 miles, the Green Flash Tasting Room will be on the left/north side of the street at Flanders Drive. From the east: From the 15 North or South exit Mira Mesa Blvd, head west for 3.6 miles, the Green Flash Tasting Room will be on the right/north side of the street at Flanders Drive.<br />
<strong>Parking:</strong> The Green Flash lot holds about 70 cars, so come early and carpool if you&#8217;d like to park there. You can also park on the street, but <strong>be very mindful that there are some poorly marked &#8216;no parking&#8217; areas, especially on Sequence where there is a center lane.</strong></p>]]></content:encoded>
      </item>
      <item>
         <title>Focus on San Diego: Life Science Conferences Spring 2012</title>
         <link>http://sdbn.org/2012/01/31/focus-on-san-diego-life-science-conferences-spring-2012/</link>
         <description>Image courtesy of user leighty (Ryan Leighty) on Flickr
This spring San Diego downtown will be buzzing with scientific discussions as our city hosts a number of major scientific symposia.  We are excited to attend and soak in all the science that will be shared during these two months.  Our own Mary Canady will also be [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92560</guid>
         <pubDate>Tue, 31 Jan 2012 18:56:20 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F31%2Ffocus-on-san-diego-life-science-conferences-spring-2012%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F31%2Ffocus-on-san-diego-life-science-conferences-spring-2012%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><div id="attachment_92568" class="wp-caption alignright" style="width:310px;"><a rel="nofollow" target="_blank" href="http://www.flickr.com/photos/leighty/3983786906/"><img src="http://sdbn.org/wp-content/uploads/2012/01/3983786906_1c60ffc097_z-300x225.jpg" alt="" title="San Diego Life Science Conferences" width="300" height="225" class="size-medium wp-image-92568"/></a><p class="wp-caption-text">Image courtesy of user leighty (Ryan Leighty) on Flickr</p></div>
<p>This spring San Diego downtown will be buzzing with scientific discussions as our city hosts a number of major scientific symposia.  We are excited to attend and soak in all the science that will be shared during these two months.  Our own Mary Canady will also be participating in a panel discussing on the triumphs and trials of <a rel="nofollow" target="_blank" href="http://www.biophysics.org/2012meeting/Program/SpecialFunctions/CareerPrograms/tabid/2458/Default.aspx#transitionacadind">Transitioning from Academia to Industry</a> at the Annual meeting of the Biophysical Society on Tuesday, February 28, 2:30 PM &#8211; 4:00 PM.</p>
<p>We hope that you are planning on attending at least some of these events, and to help you plan your attendance, we outline below pertinent information about each conference:</p>
<table class="payment" width="100%">
<tbody>
<tr>
<th width="118" valign="top">Name
<th width="60" valign="top">Date
<th width="174" valign="top">LinkedIn event page
<th width="144" valign="top">Twitter account
<th width="138" valign="top">Twitter hashtag
<th width="90" valign="top">Tweetup or Event
</tr>
<tr>
<td width="118" valign="top"><a rel="nofollow" target="_blank" href="http://www.slas2012.org/">2012 Society for Laboratory Automation &#038; Screening</a></td>
<td width="60" valign="top">2/4- 2/9</td>
<td width="174" valign="top"><a rel="nofollow" target="_blank" href="http://linkd.in/uVMlgx">http://linkd.in/uVMlgx</a></td>
<td width="144" valign="top"><a rel="nofollow" target="_blank" href="http://twitter.com/SLAS_Org">@SLAS_org</a></td>
<td width="138" valign="top">#SLAS2012</td>
<td width="90" valign="top">No<sup>*</sup></td>
</tr>
<tr>
<td width="118" valign="top"><a rel="nofollow" target="_blank" href="http://www.biophysics.org/2012meeting/Main/tabid/2386/Default.aspx">Biophysical Society 56th Annual Meeting</a></td>
<td width="60" valign="top">2/25- 2/29</td>
<td width="174" valign="top"><a rel="nofollow" target="_blank" href="http://linkd.in/uwFbH6">http://linkd.in/uwFbH6</a></td>
<td width="144" valign="top"><a rel="nofollow" target="_blank" href="http://twitter.com/BiophysicalSoc">@BiophysicalSoc</a></td>
<td width="138" valign="top">#bps12</td>
<td width="90" valign="top">No<sup>*</sup></td>
</tr>
<tr>
<td width="118" valign="top"><a rel="nofollow" target="_blank" href="http://www.ibclifesciences.com/BDPWeek/overview.xml">IBC&#8217;s Biopharmaceutical Development &amp; Production Week</a></td>
<td width="60" valign="top">2/27- 3/2</td>
<td width="174" valign="top"><a rel="nofollow" target="_blank" href="http://linkd.in/rZVttm">http://linkd.in/rZVttm</a></td>
<td width="144" valign="top"><a rel="nofollow" target="_blank" href="http://twitter.com/ibcusa">@ibcusa</a></td>
<td width="138" valign="top">#BDPWeek</td>
<td width="90" valign="top">No<sup>*</sup></td>
</tr>
<tr>
<td width="118" valign="top"><a rel="nofollow" target="_blank" href="http://www.acs.org/sandiego2012">American   Chemical Society</a></td>
<td width="60" valign="top">3/25- 3/29</td>
<td width="174" valign="top"><a rel="nofollow" target="_blank" href="http://t.co/KRDiF1b2">http://linkd.in/AgWH30</a></td>
<td width="144" valign="top"><a rel="nofollow" target="_blank" href="http://twitter.com/ACSNatlMtg">@ACSNatlMtg</a></td>
<td width="138" valign="top">#ACSSanDiego</td>
<td width="90" valign="top">Follow <a rel="nofollow" target="_blank" href="https://twitter.com/#%21/pidgirl">@pidgirl</a> for details</td>
</tr>
<tr>
<td width="118" valign="top"><a rel="nofollow" target="_blank" href="http://experimentalbiology.org/EB/pages/default.aspx?splashpage=1">Experimental Biology</a></td>
<td width="60" valign="top">4/21- 4/25</td>
<td width="174" valign="top"><a rel="nofollow" target="_blank" href="http://linkd.in/taE6N6">http://linkd.in/taE6N6</a></td>
<td width="144" valign="top"><a rel="nofollow" target="_blank" href="http://twitter.com/expbio">@expbio</a></td>
<td width="138" valign="top"><span style="text-decoration:line-through;">#</span>EB2012</td>
<td width="90" valign="top">TBD</td>
</tr>
</tbody>
</table>
<p>*SDBN may host a tweetup if none will be planned by meeting organizers.  Stay tuned.</p>
<p>The spring will be exciting for science in San Diego, add our <a rel="nofollow" target="_blank" href="http://sdbn.org/calendar">Google calendar</a> to yours so you won’t miss out on any local events. We hope you can set aside some time to take advantage of the presence of these major conferences in our city, we&#8217;ll be posting updates if you can&#8217;t. Some of the conferences have free or reasonable exhibit hall passes, and we&#8217;ll also post after hours events on our <a rel="nofollow" target="_blank" href="http://facebook.com/sdbiotech">Facebook page</a> so you can do some networking.</p>
<p>Comprendia is giving free social media consultations for your life science business, <a rel="nofollow" target="_blank" href="http://comprendia.com/contact">contact us</a> to schedule one while you’re in San Diego.</p>]]></content:encoded>
      </item>
      <item>
         <title>TEMPORARY MANAGER OR SR. MANAGER, BIOANALYTICAL</title>
         <link>http://sdbn.org/2012/01/05/temporary-manager-or-sr-manager-bioanalytical/</link>
         <description>Hiring Company: Halozyme Therapeutics
Job Code: 2011-2852-Sr. Mrg
Location: San Diego
Job Type: Preclinical Development &amp;#8211; Bioanalytical &amp;#38; Pharmacokinetics
Compensation: $ Commensurate with experience
Description: POSITION SUMMARY:
The qualified individual will be responsible for the development, implementation and interpretation of various bioanalytical (PK, immunogenicity, and pharmacodynamic biomarker) assays used to support pre-clinical and clinical development of product candidates in development. Studies [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92209</guid>
         <pubDate>Fri, 06 Jan 2012 00:12:42 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F05%2Ftemporary-manager-or-sr-manager-bioanalytical%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F05%2Ftemporary-manager-or-sr-manager-bioanalytical%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Halozyme Therapeutics</p>
<p><b>Job Code</b>: 2011-2852-Sr. Mrg</p>
<p><b>Location</b>: San Diego</p>
<p><b>Job Type</b>: Preclinical Development &#8211; Bioanalytical &amp; Pharmacokinetics</p>
<p><b>Compensation</b>: $ Commensurate with experience</p>
<p><b>Description</b>: POSITION SUMMARY:<br />
The qualified individual will be responsible for the development, implementation and interpretation of various bioanalytical (PK, immunogenicity, and pharmacodynamic biomarker) assays used to support pre-clinical and clinical development of product candidates in development. Studies will focus on bioanalytical assay development-quantify in vivo levels of drug (and metabolites) for assessing pharmacokinetic parameters of drug candidates in accordance with current guidelines and industry standards.<br />
The candidate will be an energetic hands-on laboratory scientist responsible for the design, development, optimization, qualification and implementation of bioanalytical assays with proven leadership qualities. This includes planning and execution of various types of assay systems (e.g. enzymatic assays, immunoassay, immunogenicity assays, cell-based assays, biochemical assays, and biomarker assay development) to quantify drug levels and activity in various matrices as well as supervising at least one associate. The individual must be organized and efficient and -able to work on multiple programs independently with minimal direction to meet corporate goals and objectives. A successful candidate will also have strong interpersonal skills to communicate results to colleagues in a timely manner as well as provide oversight for activities at Contract Research Organizations The successful candidate will represent Bioanalytical on.internal and external project teams. </p>
<p>ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:<br />
These include, but are not limited to:<br />
•     Significant knowledge and hands on experience with an excellent understanding of method development and troubleshooting; preference for experiences with immunoassay techniques, ELISA, neutralizing antibody assay; kinetic assays for enzyme activity, and/or LC/MS quantification.<br />
•    Ability to independently design, execute and interpret experiments in order to generate technical reports.<br />
•    Clear and effective written and verbal communication skills.<br />
•    Strong interpersonal skills including excellent verbal and written communications skills, time management, decision-making, presentation, and human relations skills.<br />
•	Lead and supervise the bioanalytical group as well as bioanalytical studies at CROs,<br />
•	Collaborate with scientists within pre-clinical and other departments and play a key role<br />
•	representing BA on project teams.<br />
•	The ability to handle multiple projects simultaneously and work in a fast-paced environment.<br />
•	Participate in preparation of regulatory submissions.<br />
?<br />
ADDITIONAL FUNCTIONS AND RESPONSIBILITIES:</p>
<p>•	Technical support of pre-clinical pharmacology, toxicology, and bioanalytical sciences groups as<br />
required.<br />
•	Other functions as determined by the pre-clinical group. </p>
<p>•	Other duties as assigned.</p>
<p>EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES REQUIRED:</p>
<p>•	B.A., B.S. or M.S. in Biological Sciences or equivalent experience, with a<br />
minimum of 12 years of experience in a bioanalytical/analytical laboratory<br />
environment, and demonstrated leadership or management experience for at least<br />
three years. Alternatively, a Ph.D. in Biological Sciences or equivalent experience,<br />
with 8-10 years of experience in a bioanalytical/analytical laboratory environment,<br />
and demonstrated leadership or management experience for three or more years.<br />
•	Candidates must have knowledge and work experience in bioassay method<br />
development (e.g. LC/MS, immunoassay, ELISA, ECL biomarker methodology and<br />
strategies, cell-based assays), optimization, qualification/validation.<br />
•	Operating knowledge of suitable computer software packages.<br />
•	 Ability to write clear, concise technical reports and attention to detail is essential.<br />
•	 Demonstrated leadership or management experience for three or more years.<br />
•	 Demonstrated experience managing extramural programs at Contract Research<br />
Organizations.<br />
•	Familiarity with GLPs is desirable.<br />
•	Hands-on experience with regulatory submissions </p>
<p>TECHNICAL KNOWLEDGE REQUIRED: </p>
<p>Equipment:   PC, scanners, facsimile machine, voice mail and e-mail systems, and common office machines, or ability to be trained.  Knowledge of other equipment required: e.g., ELISA plate reader, MSD, TaqMan, HPLC, Luminex, etc.</p>
<p>Software Knowledge:  Windows, MS Office (Outlook, Word, Excel). Knowledge of other software required: Prism GraphPad, Softmax, MSD, JMP, StatLIA, WinNonlin, etc.</p>
<p>INTERNAL AND EXTERNAL RELATIONSHIPS:</p>
<p>•	It is imperative that this individual be first and foremost a team player. They will be responsible to ensure that adequate resources are available and provide regular updates to their supervisor and team members. This will require that the individual be transparent and openly communicate information in a timely manner. </p>
<p>?<br />
EFFORT REQUIRED/ENVIRONMENTAL CONDITIONS:</p>
<p>Physical Activities:  On a continuous basis, sit at desk for a long period of time; intermittently answer telephone and write or use a keyboard to communicate through written means. Some walking and lifting up to 20 lbs. may be required.  The noise level in the work environment is usually low to moderate.  The physical demands described above are representative of those that must be met by an employee to successfully perform the essential functions and responsibilities of this job.  Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions and responsibilities.</p>
<p>Laboratory Activities, if applicable:  Biology and chemical laboratory environments experience needed.  Environmental health and safety requirements also apply.</p>
<p>TRAVEL:</p>
<p>Travel may be required up to 20% of your time
</p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.halozyme.com/Careers/Career-Opportunities/default.aspx">http://www.halozyme.com/Careers/Career-Opportunities/default.aspx</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>TEMP TO HIRE – ASSOCIATE DIRECTOR – BIOANALYTICAL TECHNICAL OPERATIONS</title>
         <link>http://sdbn.org/2012/01/05/temporary-%e2%80%93-associate-director-%e2%80%93-bioanalytical-technical-operations/</link>
         <description>Hiring Company: Halozyme Therapeutics
Job Code: 2011-2853-AD
Location: San Diego
Job Type: Preclinical Development &amp;#8211; Bioanalytical &amp;#38; Pharmacokinetics 
Compensation: $ Commensurate with experience
Description: POSITION SUMMARY:
The qualified candidate will be a highly motivated and seasoned professional with experience in bioanalytical testing to support the development of recombinant biopharmaceuticals. The candidate will oversee technology transfer and technical operations for specific [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92199</guid>
         <pubDate>Fri, 06 Jan 2012 00:00:39 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F05%2Ftemporary-%25e2%2580%2593-associate-director-%25e2%2580%2593-bioanalytical-technical-operations%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F05%2Ftemporary-%25e2%2580%2593-associate-director-%25e2%2580%2593-bioanalytical-technical-operations%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Halozyme Therapeutics</p>
<p><b>Job Code</b>: 2011-2853-AD</p>
<p><b>Location</b>: San Diego</p>
<p><b>Job Type</b>: Preclinical Development &#8211; Bioanalytical &amp; Pharmacokinetics </p>
<p><b>Compensation</b>: $ Commensurate with experience</p>
<p><b>Description</b>: POSITION SUMMARY:<br />
The qualified candidate will be a highly motivated and seasoned professional with experience in bioanalytical testing to support the development of recombinant biopharmaceuticals. The candidate will oversee technology transfer and technical operations for specific GLP bioanalytical (PK, immunogenicity, and pharmacodynamic biomarker) assays that support pre-clinical and clinical testing of specific recombinant biological product candidates. </p>
<p>The candidate will be responsible for technical operations to support specific assays and critical reagents at CRO’s used to quantify in vivo levels of protein drugs and anti-drug antibodies in accordance with current guidelines and industry standards.  The individual will also be responsible for compiling datasets to support regulatory filings for specific programs.<br />
The individual must be organized and efficient and able to work on multiple programs independently with minimal direction to meet corporate goals and objectives. A successful candidate will also have strong interpersonal skills to communicate results to colleagues in a timely manner as well as provide oversight for activities at Contract Research Organizations. Finally, the candidate will generate documentation to support regulatory filings.</p>
<p>ESSENTIAL FUNCTIONS AND RESPONSIBILITIES:<br />
These include, but are not limited to:	</p>
<p>•	Significant knowledge and experience working within the regulatory framework and considerations for bioanalytical testing of recombinant biotechnology-derived products.<br />
•	Significant knowledge and experience in the pharmacokinetic evaluation of parenteral therapeutics, drug metabolism, and protein/drug properties governing their in-vivo distribution.<br />
•	The applicant must possess the ability to work effectively in a fast paced start-up setting.<br />
•	Clear and effective written (report writing) and oral communication (presentation) skills are essential.<br />
•	The candidate must have the ability to work independently as well as in a team environment. </p>
<p>ADDITIONAL FUNCTIONS AND RESPONSIBILITIES:</p>
<p>•	Technical support of pre-clinical pharmacology, clinical, and bioanalytical sciences groups as<br />
required.<br />
•	Other functions as determined by the pre-clinical group.<br />
•	Other duties as assigned.</p>
<p>?<br />
EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES REQUIRED:</p>
<p>•	Advanced degree (PHD, MD, MSc or M. Pharm) in Pharmacology or related discipline is required.<br />
•	Significant knowledge and experience working within the regulatory framework and considerations for bioanalytical testing of recombinant biotechnology-derived products.<br />
•	Bioanalytical background with at least 8-10 years experience hands on experience in a pre-clinical and clinical drug development environment.<br />
•	At least 3 years experience in evaluation of biological therapeutics, preferably in a clinical or non-clinical setting biologics environment.<br />
•	In depth knowledge of PK and PK/PD evaluation techniques preferred. Experience of working in a team environment a plus.<br />
•	Knowledge of regulatory requirements and experience in dealing with regulatory authorities either through written summaries or oral presentations is desired, but not essential.<br />
•	The individual must be very effective at technical and scientific problem solving in a project driven, multi-disciplinary international environment, able to focus and work on<br />
several projects simultaneously and must possess excellent interpersonal, leadership and<br />
•	teamwork skills with very good organizational skills.<br />
•	Must be fluent in written and spoken English. </p>
<p>TECHNICAL KNOWLEDGE REQUIRED: </p>
<p>Equipment:   PC, scanners, facsimile machine, voice mail and e-mail systems, and common office machines, or ability to be trained.  Knowledge of other equipment required: e.g., ELISA plate reader, MSD, TaqMan, HPLC, Luminex, etc.</p>
<p>Software Knowledge:  Windows, MS Office (Outlook, Word, Excel). Knowledge of other software required: Prism GraphPad, Softmax, MSD, JMP, StatLIA, WinNonlin, etc</p>
<p>INTERNAL AND EXTERNAL RELATIONSHIPS:</p>
<p>•	It is imperative that this individual be first and foremost a team player. They will be responsible to ensure that adequate resources are available and provide regular updates to their supervisor and team members. This will require that the individual be transparent and openly communicate information in a timely manner. </p>
<p>EFFORT REQUIRED/ENVIRONMENTAL CONDITIONS:</p>
<p>Physical Activities:  On a continuous basis, sit at desk for a long period of time; intermittently answer telephone and write or use a keyboard to communicate through written means. Some walking and lifting up to 20 lbs. may be required.  The noise level in the work environment is usually low to moderate.  The physical demands described above are representative of those that must be met by an employee to successfully perform the essential functions and responsibilities of this job.  Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions and responsibilities.</p>
<p>Laboratory Activities, if applicable:  Biology and chemical laboratory environments experience needed.  Environmental health and safety requirements also apply.</p>
<p>?<br />
TRAVEL:</p>
<p>Travel may be required up to 30% of your time</p>
<p>TO APPLY: Please apply directly online by going to the URL provided.</p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.halozyme.com/Careers/Career-Opportunities/default.aspx">http://www.halozyme.com/Careers/Career-Opportunities/default.aspx</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>SDBN January 23rd Speed Networking: What Are Your 2012 Goals?</title>
         <link>http://sdbn.org/2012/01/03/sdbn-january-23rd-speed-networking-what-are-your-2012-goals/</link>
         <description>It&amp;#8217;s a new year! We asked about your 2012 goals in this poll (which you can still take and get a free CST calendar) and got some thoughtful answers. We plugged the text into Tagxedo and got this word cloud which sums it up, with the top words being biotech, pharma, networking, people, learning, companies, [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=92152</guid>
         <pubDate>Wed, 04 Jan 2012 01:10:54 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F03%2Fsdbn-january-23rd-speed-networking-what-are-your-2012-goals%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2012%2F01%2F03%2Fsdbn-january-23rd-speed-networking-what-are-your-2012-goals%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><a rel="nofollow" target="_blank" href="http://sdbn.org/wp-content/uploads/2012/01/2012sdbn5a.jpg"><img src="http://sdbn.org/wp-content/uploads/2012/01/2012sdbn5asm.jpg" alt="" title="2012 San Diego Biotechnology Network Goals" width="350" height="259" class="alignright size-full wp-image-92153"/></a>
<p>It&#8217;s a new year! We asked about your 2012 goals in <a rel="nofollow" target="_blank" href="http://sdbn.org/2011/12/21/2012-sdbn-poll/">this poll</a> (which you can still take and get a free CST calendar) and got some thoughtful answers. We plugged the text into Tagxedo and got this word cloud which sums it up, with the top words being biotech, pharma, networking, people, learning, companies, job and industry. We&#8217;ll post the full results soon along with our vision for 2012, and hope to help you get started quickly with our annual speed networking event January 23rd. Bring your business cards, hone your elevator speech, and prepare to meet <a rel="nofollow" target="_blank" href="http://sdbn.org/2010/01/27/speed-networking-for-life-scientists/">as many biotech professionals as is allowed by law in one night</a>! We&#8217;ll be at our new venue <a rel="nofollow" target="_blank" href="http://www.greenflashbrew.com/tasting-room.php">Green Flash</a> which has been attracting bigger crowds, we expect more than 100 to attend. </p>
<h3>Sponsors</h3>
<table border="0">
<tbody>
<tr>
<td><strong>Premier</strong><br />
<a rel="nofollow" target="_blank" href="http://www.integrium.com/"><img src="http://sdbn.org/wp-content/uploads/2012/01/Logo-01-Small-300x132.jpg" alt="" title="Integrium" width="300" height="132" class="alignnone size-medium wp-image-92221"/></a></td>
</tr>
<tr>
<td>
<a rel="nofollow" target="_blank" href="http://ww2.cox.com/business/sandiego/home.cox"><img alt="" src="http://images.cox.com/presentation/emergence/corp/en/img/interface/header/logo-cox.gif" title="Cox Business" class="alignnone" width="165" height="62"/></a></td>
</tr>
</tbody>
</table>
<p>We have more sponsorship opportunities for this popular event, <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">contact us</a> for more details.</p>
<h3>Event Details</h3>
<p><strong>Who:</strong> Biotechnology professionals in the greater San Diego area<br />
<strong>What:</strong>SDBN January 23rd 2012 Speed Networking Event at Green Flash Tasting Room<br />
<strong>When:</strong> Monday, January 23rd 2012, 5:30-8:30 p.m.<br />
<strong>Where:</strong> Green Flash Tasting Room, 6550 Mira Mesa Boulevard, San Diego, CA 92121 (Directions below)<br />
<strong>Cost: </strong>$25/20 ($50 for recruiters) includes dinner (TBD gourmet food truck). Beverages available for purchase (30 Green Flash beers on tap, soda, complimentary water).<br />
<strong>Contact:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">http://sdbn.org/contact</a><br />
<strong>For more information about the event:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/january">http://sdbn.org/january</a><br />
<a rel="nofollow" target="_blank" href="http://sdbn.org/register"><img class="alignright size-medium wp-image-534" title="Register" src="http://sdbn.org/wp-content/uploads/2008/10/sdbnbutton_24.jpg" alt="" width="150" height="77"/></a><br />
<strong>Directions:</strong> From the west: From the 805 North or South exit Mira Mesa Blvd, head east for 2.0 miles, the Green Flash Tasting Room will be on the left/north side of the street at Flanders Drive. From the east: From the 15 North or South exit Mira Mesa Blvd, head west for 3.6 miles, the Green Flash Tasting Room will be on the right/north side of the street at Flanders Drive.<br />
<strong>Parking:</strong> The Green Flash lot holds about 70 cars, so come early and carpool if you&#8217;d like to park there. You can also park on the street, but <strong>be very mindful that there are some poorly marked &#8216;no parking&#8217; areas, especially on Sequence where there is a center lane.</strong></p>]]></content:encoded>
      </item>
      <item>
         <title>Web developer</title>
         <link>http://sdbn.org/2011/12/09/web-developer/</link>
         <description>Hiring Company: Ambry Genetics
Location: United States
Job Type: Full time
Compensation: $ Ambry Genetics offers a competitive salary commensurate with experience and qualifications. Benefits include health, dental, vision, 401K and 125c.
Description: Ambry Genetics is a thriving and fun company that provides molecular diagnostics and biotechnology services. The company is located in Aliso Viejo, California, and is rapidly [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91860</guid>
         <pubDate>Fri, 09 Dec 2011 22:16:15 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F12%2F09%2Fweb-developer%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F12%2F09%2Fweb-developer%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Ambry Genetics</p>
<p><b>Location</b>: United States</p>
<p><b>Job Type</b>: Full time</p>
<p><b>Compensation</b>: $ Ambry Genetics offers a competitive salary commensurate with experience and qualifications. Benefits include health, dental, vision, 401K and 125c.</p>
<p><b>Description</b>: Ambry Genetics is a thriving and fun company that provides molecular diagnostics and biotechnology services. The company is located in Aliso Viejo, California, and is rapidly expanding across multiple markets. We are seeking to hire a full-time Web Developer with an emphasis on visualization and presentation of biology data. </p>
<p><b>Roles and Responsibilities:</b></p>
<p>As a Web Developer in the Bioinformatics Department, the person will have the opportunity to work with scientists and programmers in various departments to develop a variety of web tools and programs with the emphasis on presenting and visualizing biological data. This is an amazing opportunity to get in to one of the fastest growing fields in the health care industry.</p>
<p><b>Required Qualifications:</b></p>
<ul>
<li>LAMP stack (Linux, Apache, PHP, MySQL).
<li>HTML, CSS, JavaScript, SQL, jQuery, jQuery UI.
<li>Knowledge of web standards and browser compatibility issues.
<li>Highly self-motivated, able to work independently and efficiently to meet deadlines.
<li>B.S. degree in Computer Science with at least 3 years of web development experience, or equivalent experience.
<p>Preferred Qualifications</p>
<li>Preference given to candidates with experience developing in the healthcare/biotech R&amp;D.
<li>Excellent organizational and time management abilities.
<li>Excellent oral and written communication skills.
</ul>
<p>
Interested candidates should submit a letter of interest and curriculum vitae to xli@ambrygen.com</p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.ambrygen.com/Careers.html#Bioinformatics Web Developer">http://www.ambrygen.com/Careers.html#Bioinformatics Web Developer</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>Bioinformatics Analyst</title>
         <link>http://sdbn.org/2011/12/09/bioinformatics-analyst-2/</link>
         <description>Hiring Company: Ambry Genetics
Location: United States
Job Type: Full time
Compensation: $ Ambry Genetics offers a competitive salary commensurate with experience and qualifications. Benefits include health, dental, vision, 401K and 125c.
Description: Ambry Genetics is a thriving and fun company that provides molecular diagnostics and genomic services. The company is located in Aliso Viejo, California, and is rapidly [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91851</guid>
         <pubDate>Fri, 09 Dec 2011 21:48:09 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F12%2F09%2Fbioinformatics-analyst-2%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F12%2F09%2Fbioinformatics-analyst-2%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Ambry Genetics</p>
<p><b>Location</b>: United States</p>
<p><b>Job Type</b>: Full time</p>
<p><b>Compensation</b>: $ Ambry Genetics offers a competitive salary commensurate with experience and qualifications. Benefits include health, dental, vision, 401K and 125c.</p>
<p><b>Description</b>: Ambry Genetics is a thriving and fun company that provides molecular diagnostics and genomic services. The company is located in Aliso Viejo, California, and is rapidly expanding across multiple markets.  We are seeking to hire a full time Bioinformatics Analyst to primarily analyze clinical sequencing data and help bioinformatics scientists to test bioinformatics pipeline.</p>
<p><b>Requirements:</b></p>
<p>Candidates should have a Bachelor or Master&#8217;s degree in Bioinformatics, Computer Science, Biology or a related field with practical experience analyzing sequencing data. </p>
<p><b>Preferred experiences:</b></p>
<ul>
<li>Work experience with Perl or Python, and VBA.
<li>Work experience with Linux/Unix system.
<li>Familiarity with SQL and PHP.
<li>Familiarity with the concepts of molecular biology and genomics.
<li>Practical experience in analyzing sequencing data, desirable next-gen sequencing.
<li>Motivated to work full time on sequencing projects using bioinformatics tools, and willing to learn new relevant skills.
<li>Ability to work both independently and in a team environment of a fast-moving genetic service company.
<li>Good oral and written communication skills.
</ul>
<p>
Ambry Genetics offers a competitive salary commensurate with experience and qualifications. Benefits include health, dental, vision, 401K and 125c. Interested candidates should submit a letter of interest and curriculum vitae to xli@ambrygen.com. </p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.ambrygen.com/Careers.html#Analyst">http://www.ambrygen.com/Careers.html#Analyst</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>Assay Validation Consultant</title>
         <link>http://sdbn.org/2011/11/22/assay-validation-consultant/</link>
         <description>Hiring Company: Virapur
Job Code: 112211
Location: San Diego
Job Type: Validation 
Compensation: $ TBD
Description: I am looking for someone to work directly with me in outlining a validation plan for an immunoassay. I need someone who has full knowledge of the issues with a  typical biological assay and can guide me in writing the plan as [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91636</guid>
         <pubDate>Wed, 23 Nov 2011 00:49:53 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F22%2Fassay-validation-consultant%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F22%2Fassay-validation-consultant%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: Virapur</p>
<p><b>Job Code</b>: 112211</p>
<p><b>Location</b>: San Diego</p>
<p><b>Job Type</b>: Validation </p>
<p><b>Compensation</b>: $ TBD</p>
<p><b>Description</b>: I am looking for someone to work directly with me in outlining a validation plan for an immunoassay. I need someone who has full knowledge of the issues with a  typical biological assay and can guide me in writing the plan as well as the validation report.  Some statistical knowledge pertinent to assay validation. The consultant should be able to put into words the validation assessment  parameters that are pertinent to this assay.  Limited project and short term  effort which could be accomplished in part by email and phone.  </p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.virapur.com/assay_services/assay_services.php">http://www.virapur.com/assay_services/assay_services.php</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>Quality Control Analyst</title>
         <link>http://sdbn.org/2011/11/18/quality-control-analyst/</link>
         <description>Hiring Company: PaxVax, Inc.
Job Code: 2055
Location: Sorrento Valley
Job Type: Biotechnology
Compensation: $ DOE
Description: Specific Responsibilities:
• Perform assigned quality control testing, which may include, but is not limited to cell based titer assay, moisture analysis, disintegration, and PCR.
• Maintenance of mammalian cell cultures
•Qualification and validation of QC test methods.
• Writes and revises standard operating procedures and other [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91582</guid>
         <pubDate>Fri, 18 Nov 2011 21:50:27 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F18%2Fquality-control-analyst%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F18%2Fquality-control-analyst%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: PaxVax, Inc.</p>
<p><b>Job Code</b>: 2055</p>
<p><b>Location</b>: Sorrento Valley</p>
<p><b>Job Type</b>: Biotechnology</p>
<p><b>Compensation</b>: $ DOE</p>
<p><b>Description</b>: Specific Responsibilities:</p>
<p>• Perform assigned quality control testing, which may include, but is not limited to cell based titer assay, moisture analysis, disintegration, and PCR.</p>
<p>• Maintenance of mammalian cell cultures</p>
<p>•Qualification and validation of QC test methods.</p>
<p>• Writes and revises standard operating procedures and other related GLP/GMP documentation.</p>
<p>• Performance of data entry and trend analysis and ensures laboratory data integrity and traceability.</p>
<p>• Manages test samples, reagents and reference standards used in the laboratory.</p>
<p>• Develop and optimize QC test methods, as required.</p>
<p>• Reviews data obtained for compliance to specifications and reports abnormalities.</p>
<p>• Trains personnel on quality control methods and procedures<br />
• Provides back-up assistance for other QC systems such as the Environmental program and raw materials.</p>
<p>Qualifications:</p>
<p>•Degree in Biology or Life Sciences related discipline with a minimum of three (3) years experience performing assays in a GMP-regulated environment.</p>
<p>• Possess a strong work ethic along with a solid organizational, time management, problem-solving, decision-making, judgment, and interpersonal skills. </p>
<p>• Demonstrate an ability to think and act independently; accept supervision, work quickly and accurately in a fast-paced environment, critically analyze data and proactively solve problems. </p>
<p>Background:</p>
<p>PaxVax is an innovative and fast-paced vaccine start-up company developing vaccine candidates against several important infectious diseases, including influenza, cholera and HIV. The Company’s first vaccine candidate for H5N1 or “bird flu” recently completed a successful Phase 1 clinical trial. In the coming year PaxVax plans to initiate three additional clinical trials on its candidates. The Company has committed funding of over million to support its operation including R&amp;D and its own licensed GMP manufacturing facility. PaxVax has 45 employees organized by functional departments and cross-functional project teams for each of its vaccine candidates. PaxVax is a double bottom line business focused on delivering both financial as well as social returns in global health.</p>
<p>Benefits: Company sponsored employee medical and dental benefits, 401k, STD &amp; LTD coverage. Competitive compensation. No relocation assistance is available.</p>
<p>PaxVax is an Equal Opportunity Employer. </p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.paxvax.com">http://www.paxvax.com</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>Project Manager – Leader</title>
         <link>http://sdbn.org/2011/11/18/project-manager-leader/</link>
         <description>Hiring Company: PaxVax, Inc.
Job Code: 2056
Location: Sorrento Valley
Job Type: Biotechnology
Compensation: $ DOE
Description:
Summary of Position: 
The Project Manager will be a key member of the Project Management team, reporting directly to the Vice President of Project Management and located at our San Diego site.  The Project Manager will work closely with internal functional department heads [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91572</guid>
         <pubDate>Fri, 18 Nov 2011 17:40:56 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F18%2Fproject-manager-leader%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F18%2Fproject-manager-leader%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><b>Hiring Company</b>: PaxVax, Inc.</p>
<p><b>Job Code</b>: 2056</p>
<p><b>Location</b>: Sorrento Valley</p>
<p><b>Job Type</b>: Biotechnology</p>
<p><b>Compensation</b>: $ DOE</p>
<p><b>Description</b>:
<p>Summary of Position: </p>
<p>The Project Manager will be a key member of the Project Management team, reporting directly to the Vice President of Project Management and located at our San Diego site.  The Project Manager will work closely with internal functional department heads (research, manufacturing, clinical) and external vendors and consultants (toxicology and regulatory) to oversee and direct the schedule and budget of candidate vaccine programs.  The Project Manager will also assist the VP in the growth and development of project management systems for the company including project leadership and financial reporting and integration.</p>
<p>Primary Responsibilities:</p>
<p>o	Develop and monitor project plans, resources, timelines and budgets to ensure alignment with  corporate objectives </p>
<p>o	Schedule, lead and facilitate project team meetings: prepare and issue  agendas, presentations, minutes, action items;  Communicate regularly with milestone champions to track milestone achievements and monitor key deliverables</p>
<p>o	Facilitate and resolve any conflicts between functional departments amongst the senior executive team</p>
<p>o	Work closely with CFO and finance department to develop and track project expenses, internal and external, FTE  hours, and vendor billings and identify variances to budget and communicate issues that could impact that budget</p>
<p>o	Analyze contracts (MTAs, CDAs, etc) and proposals and identify potential issues in advance and suggest measures to mitigate and/or manage risks </p>
<p>o	Prepare and issue requests for proposals, schedule presentations as needed, and summarize proposals for executive team/VP.</p>
<p>o	Keep executive team/VP informed of current and anticipated expenses of key contracts.  May troubleshoot invoices and work with internal accounting staff and vendors to correct any problems</p>
<p>o	May manage vendor relationship and expectations and builds a collaborative relationship with the vendor</p>
<p>o	Review and write business correspondence</p>
<p>o	Research potential funding sources to coincide with the funding focus of the company</p>
<p>o	Manage the grant funding budget and accounting process as needed</p>
<p>Requirements: </p>
<p>o	BS required, MS/Ph.D preferred</p>
<p>o	Requires 5 years of successful project management experience in life science industry</p>
<p>o	Expert knowledge of basic science and drug development functional areas: cellular assays, preclinical models of efficacy and toxicology, clinical and regulatory affairs, clinical operations, formulation and manufacturing. (Specific experience with biologics and/or vaccine experience is a plus) </p>
<p>o	Ability to quickly assess problems/situations and provide effective resolution/solutions as well as proven success at team leadership, facilitation and conflict resolution</p>
<p>o	In depth knowledge of Microsoft Project and Microsoft Project Server required </p>
<p>o	Detail oriented and extremely organized; ability to prioritize multiple project deliverables </p>
<p>o	Strong mathematical/financial skills, familiarity with project cost accounting, government contracts</p>
<p>o	Ability to multi-task and prioritize efficiently across multiple projects/sub-projects</p>
<p>o	Strong analytical and interpersonal skills, as well as the ability to motivate and influence; vendor interface experience and strong negotiating skills </p>
<p>o	Excellent written and oral communication skills </p>
<p>o	Ability to multitask and work both in a team environment as well as independently as required </p>
<p>o	Ability to handle details of a highly confidential and critical nature</p>
<p>o	Proficiency with Microsoft Office products, in particular Word, Excel, PowerPoint, Outlook and Visio </p>
<p>o	Language skills a plus</p>
<p>Background:</p>
<p>PaxVax is an innovative and fast-paced vaccine start-up company developing vaccine candidates against several important infectious diseases, including influenza, cholera and HIV. The Company&#8217;s first vaccine candidate for H5N1 or &#8220;bird flu&#8221; recently completed a successful Phase 1 clinical trial. In the coming year PaxVax plans to initiate three additional clinical trials on its candidates. The Company has committed funding of over  million to support its operation including R&amp;D and its own licensed GMP manufacturing facility. PaxVax has 45 employees organized by functional departments and cross-functional project teams for each of its vaccine candidates. PaxVax is a double bottom line business focused on delivering both financial as well as social returns in global health.</p>
<p>Benefits: Company sponsored employee medical and dental benefits, 401k, STD &amp; LTD coverage. Competitive compensation. No relocation assistance is available.</p>
<p>PaxVax is an Equal Opportunity Employer. </p>
<p><b>Link for more information</b>: <a rel="nofollow" target="_blank" href="http://www.paxvax.com">http://www.paxvax.com</a></p>]]></content:encoded>
         <category>Featured Jobs</category>
      </item>
      <item>
         <title>SDBN 3rd Anniversary Party December 12th 2011 at Green Flash</title>
         <link>http://sdbn.org/2011/11/17/3rd-anniversary-party-december-12th-at-green-flash/</link>
         <description>Can you believe the San Diego Biotechnology Network is three years old now? We held our first SDBN event in November of 2008, and our objective was to improve networking opportunities for local biotech professionals. After 3 years, how are we doing? We&amp;#8217;d like to celebrate and also get your feedback on how we can [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91550</guid>
         <pubDate>Thu, 17 Nov 2011 19:02:32 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F17%2F3rd-anniversary-party-december-12th-at-green-flash%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F17%2F3rd-anniversary-party-december-12th-at-green-flash%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><a rel="nofollow" target="_blank" href="http://sdbn.org/wp-content/uploads/2011/11/SDBN3rdanniversary.jpg"><img src="http://sdbn.org/wp-content/uploads/2011/11/SDBN3rdanniversary.jpg" alt="" title="SDBN3rdanniversary" width="300" height="160" class="alignright size-full wp-image-91551"/></a>Can you believe the San Diego Biotechnology Network is three years old now? We held our <a rel="nofollow" target="_blank" href="http://sdbn.org/2008/10/14/november-event/">first SDBN event</a> in November of 2008, and our objective was to improve networking opportunities for local biotech professionals. After 3 years, how are we doing? We&#8217;d like to celebrate and also get your feedback on how we can help you even more in 2012. Join us again at <a rel="nofollow" target="_blank" href="http://www.greenflashbrew.com/tasting-room.php">Green Flash in Mira Mesa</a> from 5:30-8:30 p.m. December 12th for some great networking, food, and beer (for purchase, non-alcoholic beverages available as well). <a rel="nofollow" target="_blank" href="http://sdbn.org/2011/11/04/sdbn-happy-hour-and-linkedin-tips/">Last time</a> we had upwards of 130 people, and this time we&#8217;ve got the place to ourselves and we&#8217;ll also get tours of the facility. Beer is biochemistry, and two of the founders of Green Flash worked at Invitrogen back in the day!</p>
<p>In addition, we&#8217;ll do the ever popular &#8216;introduce a colleague&#8217; activity. We’ll collect business cards from those interested in participating, each take one, then find and learn about the person we each drew. Then, we’ll each introduce the person we drew at the microphone. It&#8217;s a great way to meet people, practice your presentation skills, and get exposure.</p>
<h3>Sponsors</h3>
<table border="0">
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.omnicomm.com/"><img src="http://sdbn.org/wp-content/uploads/2011/11/omnicomm_sm-300x79.gif" alt="" title="omnicomm_sm" width="175" class="aligncenter size-medium wp-image-91626"/></a></td>
<td><a rel="nofollow" target="_blank" href="http://lancasterlabs.com/"><img src="http://sdbn.org/wp-content/uploads/2011/11/50-logo-RGB-150-pix.jpg" alt="" title="Lancaster Laboratories" width="175" class="alignnone size-full wp-image-91660"/></a></td>
<td><a rel="nofollow" target="_blank" href="http://explorabiolabs.com/"><img src="http://sdbn.org/wp-content/uploads/2011/07/Explora-logo_sm.jpg" alt="" title="Explora BioLabs" width="175" class="alignnone size-full wp-image-60232"/></a></td>
</tr>
</table>
<p>This event is available for sponsorship, <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">contact us</a> for more information.</p>
<h3>Event Details</h3>
<p><strong>Who:</strong> Biotechnology professionals in the greater San Diego area<br />
<strong>What:</strong>SDBN December 12th 2011 3rd Anniversary Party at Green Flash Tasting Room<br />
<strong>When:</strong> Monday, December 12th 2011, 5:30-8:30 p.m.<br />
<strong>Where:</strong> Green Flash Tasting Room, 6550 Mira Mesa Boulevard, San Diego, CA 92121 (Directions below)<br />
<strong>Cost: </strong>$25/20 ($50 for recruiters), includes dinner (TBD gourmet food truck). Beverages available for purchase (30 Green Flash beers on tap, soda, complimentary water)<br />
<strong>Contact:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/contact">http://sdbn.org/contact</a><br />
<strong>For more information about the event:</strong> <a rel="nofollow" target="_blank" href="http://sdbn.org/december">http://sdbn.org/december</a><br />
<a rel="nofollow" target="_blank" href="http://sdbn.org/register"><img class="alignright size-medium wp-image-534" title="Register" src="http://sdbn.org/wp-content/uploads/2008/10/sdbnbutton_24.jpg" alt="" width="150" height="77"/></a><br />
<strong>Directions:</strong> From the west: From the 805 North or South exit Mira Mesa Blvd, head east for 2.0 miles, the Green Flash Tasting Room will be on the left/north side of the street at Flanders Drive. From the east: From the 15 North or South exit Mira Mesa Blvd, head west for 3.6 miles, the Green Flash Tasting Room will be on the right/north side of the street at Flanders Drive.<br />
<strong>Parking:</strong> The Green Flash lot holds about 70 cars, so come early and carpool if you&#8217;d like to park there. You can also park on the street, but <strong>be very mindful that there are some poorly marked &#8216;no parking&#8217; areas, especially on Sequence where there is a center lane.</strong></p>]]></content:encoded>
      </item>
      <item>
         <title>SDBN Happy Hour and LinkedIn Tips for Biotech Professionals</title>
         <link>http://sdbn.org/2011/11/04/sdbn-happy-hour-and-linkedin-tips/</link>
         <description>What a great turnout last week!  Thanks to all who attended SDBN&amp;#8217;s first Happy Hour event, and thanks to our sponsor Avitus Group.  As always we enjoyed seeing many familiar as well as new faces within the local scientific community.  
Congratulations to Ramy Aziz, Visiting Scientist at UCSD Systems Biology Research Group, who [...]</description>
         <guid isPermaLink="false">http://sdbn.org/?p=91122</guid>
         <pubDate>Fri, 04 Nov 2011 20:37:22 +0000</pubDate>
         <content:encoded><![CDATA[<div class="tweetmeme_button" style="float:left;margin-right:10px;">
			<a rel="nofollow" target="_blank" href="http://api.tweetmeme.com/share?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F04%2Fsdbn-happy-hour-and-linkedin-tips%2F"><br />
				<img src="http://api.tweetmeme.com/imagebutton.gif?url=http%3A%2F%2Fsdbn.org%2F2011%2F11%2F04%2Fsdbn-happy-hour-and-linkedin-tips%2F&amp;source=sdbn&amp;style=normal&amp;b=2" height="61" width="50"/><br />
			</a>
		</div>
<p><a rel="nofollow" target="_blank" href="http://sdbn.org/wp-content/uploads/2011/11/SDBN-pic2.jpg"><img src="http://sdbn.org/wp-content/uploads/2011/11/SDBN-pic2-300x225.jpg" alt="SDBN, biotech, biotechnology" title="SDBN Happy Hour at the Green Flash Tasting Room" width="300" height="225" class="alignright size-medium wp-image-91267"/></a>
<p>What a great turnout last week!  Thanks to all who attended <a rel="nofollow" target="_blank" href="http://sdbn.org/2011/10/06/sdbn-october-26th-happy-hour-at-green-flash-tasting-room/">SDBN&#8217;s first Happy Hour event</a>, and thanks to our sponsor <a rel="nofollow" target="_blank" href="http://www.avitusgroup.com/">Avitus Group</a>.  As always we enjoyed seeing many familiar as well as new faces within the local scientific community.  </p>
<p>Congratulations to Ramy Aziz, Visiting Scientist at UCSD Systems Biology Research Group, who was the big winner.  A social butterfly collecting more than 25 business cards, he collected the prize of a $50 Amazon gift card &#8211; thanks Avitus Group!</p>
<p>
We appreciate everyone who was able to participate in our LinkedIn Profile recommendations, it was a definite hit.</p>
<p><b>With so many ways to improve a LinkedIn profile it&#8217;s not easy to narrow down the ideas.</b></p>
<p>Whether you&#8217;re a scientist looking for a job, or trying to increase your reputation within your industry, spiffing up your LinkedIn page to reflect where you are and what you can offer can be invaluable to your career growth.  </p>
<p>We saw some great examples of LinkedIn pages.   And since we saw several recurring themes of areas where people could use help, in this blog post I&#8217;ll stick with some of the basic improvement areas.  </p>
<p>Before getting into it, here was a common question we heard &#8211; “Why should I care if I’m not currently a job seeker?”  Answer &#8211; because if you wait until you absolutely <em>need</em> a network to leverage, you will find yourself a few months behind the game.  If you can build a foundation now, you’ll have it when you need it, and more than that, you never know when or where new opportunities will come from….</p>
<p>Below is a summary of five (5) characteristics common to profiles that:</p>
<ul>
<li>have a <strong>likely chance of being found through a LinkedIn search</strong>, or </li>
<li>that act as an <strong>engaging, interesting, and informative personal marketing piece for professional deliverables and qualifications</strong> </li>
</ul>
<h3>Top LinkedIn Profile Improvements &#8211; Starting Points</h3>
<p></p>
<ol>
<li><strong>Have a photo</strong> &#8211; A headshot where you’re not holding a beer is the path you want to take.  You wouldn’t have a bag over your head at a networking event, and you shouldn’t here.  LinkedIn is a conversation waiting to happen &#8211; be friendly and you’ll start the conversation on the right foot.
</li>
<li><strong>Get a Customized URL</strong> &#8211; Take advantage of personalizing your URL – make it shorter and more memorable – here’s how:
<ol>
<table border="1">
<tbody>
<tr>
<td style="text-align:left;border-color:#ffffff;padding:5px;" width="300" valign="top" bgcolor="#dfdfdf"><strong>Option 1</strong></td>
<td style="text-align:left;border-color:#ffffff;padding:5px;" width="300" valign="top" bgcolor="#dfdfdf"><strong>Option 2</strong></td>
</tr>
<tr>
<td style="padding:5px;border-color:#ffffff;" width="300" valign="top" bgcolor="#dfdfdf">
<ol>
<li>Go to your Profile Page</li>
<li>At the bottom of the grey box with all of your information is a Public Profile line</li>
<li>You should see an “Edit” link next to your URL</li>
<p>
<a rel="nofollow" target="_blank" href="http://sdbn.org/wp-content/uploads/2011/11/Screen-shot-2011-11-02-at-4.14.50-PM.png"><img src="http://sdbn.org/wp-content/uploads/2011/11/Screen-shot-2011-11-02-at-4.14.50-PM-300x42.png" alt="sdbn, biotech, linkedin, linkedin tips" width="270" height="42" class="alignnone size-medium wp-image-91159"/></a></p>
<li>Click &#8220;Edit&#8221; and enter your personalized URL (then save)</li>
</ol>
</td>
<td style="padding:5px;border-color:#ffffff;" width="300" valign="top" bgcolor="#dfdfdf"><em>Adapted from <a rel="nofollow" target="_blank" href="https://help.linkedin.com/app/answers/detail/a_id/87">LinkedIn Help Center</a></em>
<ol>
<li>Go to Settings and click &#8220;Edit your public profile&#8221;</li>
<li>In the &#8220;Your public profile URL&#8221; box on the right, click the &#8220;Customize your public profile URL&#8221; link</li>
<li>Type the last part of your new custom URL in the text box</li>
<li>Click Set Custom URL and enter your personalized URL (then save)</li>
</ol>
</td>
</tr>
</tbody>
</table>
</ol>
</li>
<p>&nbsp;</p>
<li><strong>Professional Headline &#8211; </strong>Your Name and Professional Headline are the only two<strong> </strong>things that others will see in the some places in LinkedIn.
<p>For example, people mouse over your name for this information within <strong>Group discussions</strong>, in the <strong>Q&amp;A section</strong> (if you ask / answer a question), and <strong>in connections lists</strong>.</p>
<ul>
<li>Your headline should be a marketing phrase, not just your current title (current title appears under “Current” in the information section anyway)</li>
<li> You are allowed 120 characters in this field so try to add some detail to let people know who you are and what you can do for them, in a nutshell</li>
</ul>
</li>
<p>&nbsp;</p>
<li><strong>Join more groups &#8211; You get 50 for free, take advantage. </strong>Find the most relevant LinkedIn groups in your industry that will help you meet your goals.  You may join because you get something from their discussions or you may join because an influencer or connection at a company you&#8217;re interested in is in that group.  Over time you can filter out the groups that offer you little or nothing.
<ul>
<li>Find jobs in groups &#8211; people post these things, especially in job seeker groups within your industry (see some suggested groups in the last bullet)</li>
<li>Groups are a great place to find others who are having discussions in your field, about topics of interest to you.  And if you need help with anything, it’s a perfect place to ask for advice.  Ask questions &#8211; you’ll learn and it raises your profile in LinkedIn.</li>
<li>Listen &#8211; The great thing about groups is you don’t have to talk at all.  This is probably the best way to get a feel for the topics and content valued in your primary groups of interest, which leads to the next point -</li>
<li>You don’t have to follow everything in every group &#8211; just pick a few most interesting or valuable to you</li>
<li>Want to showcase your expertise in your field? Giving advice within groups builds your reputation in your industry</li>
<li>Reach many more people directly &#8211; within your field.  And when you want to LinkIn with someone, you can use a group as a point of connection when sending the invitation</li>
<li><em><strong>Here are some LinkedIn groups we at SDBN recommend for scientists (job-seeking or not)</strong></em> &#8211;<br />
<table border="1" width="480" style="text-align:left;border-color:#ffffff;padding:5px;" bgcolor="#dfdfdf">
<tr>
<td align="center"><strong>Group</strong></td>
<td align="center"><strong>No. of Members</strong></td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups?gid=51209">American Chemical Society</a></td>
<td>9,085</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=2689706&amp;impid=&amp;pgkey=anet_search_results&amp;actpref=anetsrch_name&amp;trk=anetsrch_name&amp;goback=%2Egdr_1320358373169_1">BIO International Convention</a></td>
<td>1,534</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups?gid=1668837&amp;goback=%2Egdr_1320357258678_1%2Egmp_127165%2Egdr_1320357258680_1%2Egmp_1668837">BIOCOM</a></td>
<td>1,299</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups?gid=127165&amp;goback=%2Egdr_1320357258678_1%2Egmp_127165"> Biospace</a></td>
<td>3,987</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=60035&amp;impid=60035-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">Biotech &amp; Pharma Professionals Network</a></td>
<td>97,687</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=87134&amp;impid=87134-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">Biotechnology/Pharmaceuticals</a></td>
<td>18,816</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups?gid=2265590&amp;goback=%2Egdr_1320357258678_1%2Egmp_127165%2Egdr_1320357258680_1%2Egmp_1668837%2Egdr_1320357258682_1%2Egmp_2265590">Drug Discovery 2.0</a></td>
<td>542</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=2331907&amp;impid=2331907-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">Life Science Talk</a></td>
<td>5,055</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=72923&amp;impid=72923-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">The Life Science Executive Exchange</a></td>
<td>14,716</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=36798&amp;impid=36798-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">Lifesciences Opportunities in US</a></td>
<td>29,762</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups/LiMS-forum-Laboratory-Informatics-Institute-2069898?itemaction=mclk&amp;anetid=2069898&amp;impid=2069898-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">LiMS forum &#8211; Laboratory Informatics Institute user&#8217;s group for LIMS, Scientific &amp; Health Informatics</a></td>
<td>31,406</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups/myBIO-Community-Biotechnology-connections-35214?trk=myg_ugrp_ovr">myBIO Community &#8211; Biotechnology connections</a></td>
<td>17,137</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups?gid=2103800&amp;goback=%2Egdr_1320357258678_1%2Egmp_127165%2Egdr_1320357258680_1%2Egmp_1668837%2Egdr_1320357258682_1%2Egmp_2265590%2Egdr_1320357258684_1%2Egmp_2103800">Pharmaceutical Jobs Biotech Life Sciences &amp; Medical Devices</a></td>
<td> 54,869</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groupsDirectory?itemaction=mclk&amp;anetid=61852&amp;impid=61852-35214&amp;pgkey=anet_about&amp;actpref=anet_about-gbm&amp;trk=anet_about-gbm-group&amp;goback=%2Eanb_35214_*2">Professionals in the Pharmaceutical and Biotech Industry</a></td>
<td>64,471</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups/San-Diego-Biotech-Pharma-Professional-143772?goback=%2Egdr_1320357258678_1%2Egmp_127165%2Egdr_1320357258680_1%2Egmp_1668837%2Egdr_1320357258682_1%2Egmp_2265590%2Egdr_1320357258684_1%2Egmp_2103800%2Egdr_1320357258686_1%2Egmp_143772">San Diego Biotech Pharma Professional Social Network</a></td>
<td>1,299</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups?gid=876387">San Diego Biotechnology Network</a></td>
<td>5,179</td>
</tr>
<tr>
<td><a rel="nofollow" target="_blank" href="http://www.linkedin.com/groups/SoCal-Science-Cafe-Career-Cafe-54400?trk=myg_ugrp_ovr">SoCal Science Cafe: Career Cafe</a></td>
<td>105</td>
</tr>
</table>
</li>
</ul>
</li>
<p>&nbsp;</p>
<li><strong>More Recommendations &#8211; </strong>One of the best ways to stand out to employers, recruiters, or potential business partners is through testimonials of others who have done business or worked side-by-side with you.
<ul>
<li><strong> </strong>Ask for a recommendation from as many people as possible and be sure to return the favor</li>
<li><strong> </strong>What you say about others can also inform on if you work and play well with other scientists.  And these also show up on your Profile page so don’t just “form-letter” your recommendations &#8211; make them personal, interesting, and genuine.</li>
</ul>
</li>
</ol>
<p>So basically, the idea to remember is to fill our your LinkedIn profile page out as completely as you would your resum&eacute; .  Since you want your LinkedIn profile to be more succinct than your resum&eacute; , go through and add sections manually rather than relying on the resum&eacute; upload function.  I haven&#8217;t tried it myself but have heard that it can mess up the formatting you&#8217;ve already created.  Plus you&#8217;ll have to go back and edit it anyway, so you may as well just start there.  </p>
<p>We hope these tips help you to improve your LinkedIn profile through some relatively painless starting points. <em><strong>Please leave any tips you have in the comments below &#8211; and we’ll be sure to follow this post up with some intermediate and advanced tips for LinkedIn profile improvement, stay tuned.</strong></em></p>]]></content:encoded>
      </item>
   </channel>
</rss><!-- fe12.pipes.sp1.yahoo.com compressed/chunked Thu May 31 10:48:04 UTC 2012 -->

